Delivery of cardiac stimulation devices

Description

TECHNICAL FIELD

This document relates to systems that electrically stimulate cardiac or other tissue and to systems for delivering stimulation devices.

BACKGROUND

Pacing instruments can be used to treat patients suffering from any of a number of heart conditions, such as a reduced ability to deliver sufficient amounts of blood from the heart. For example, some heart conditions may cause or be caused by conduction defects in the heart. These conduction defects may lead to irregular or ineffective heart contractions. Cardiac pacing systems (e.g., a pacemaker or an implantable defibrillator with pacing capability) may be implanted in a patient's body so that wire electrodes in contact with the heart tissue provide electrical stimulation to regulate electrical conduction in the heart tissue. Such regulated electrical stimulation is done to cause the heart to contract and hence pump blood.

The wired pacing systems in current use include a pulse generator that is implanted, typically in a patient's pectoral region just under the skin. One or more wired leads extend from the pulse generator so as to contact various portions of the heart. An electrode at a distal end of a lead may provide the electrical contact to the heart for delivery of the electrical pulses generated by the pulse generator and delivered to the electrode through the lead.

The use of wired leads may limit the number of sites of heart tissue at which electrical energy may be delivered. For example, most commercially available pacing leads are not indicated for use inside the left chambers of the heart. One reason is that the high pumping pressure in the left chambers of the heart may cause a thrombus or clot that forms on the bulky wired lead to eject into distal arteries, thereby causing stroke or other embolic injury. Thus, in order to pace the left side of the heart with a wired lead, most wired leads are directed through the cardiac venous system (outside the left chambers of the heart) to a site in a cardiac vein along the exterior of the left side of the heart.

In one example of a pacing therapy that includes pacing of a left heart chamber, a treatment known as biventricular pacing may be performed when the left ventricle does not contract in synchrony with the right ventricle. In order to perform such pacing therapy, typically a first wired lead is implanted through a vein into the right atrium, a second wired lead is implanted through a vein into the right ventricle, and a third wired lead is implanted through a vein and into the coronary sinus vein (to pace the left ventricle wall from outside the left ventricle). These three wired leads may be connected to a pacemaker device (e.g., implanted in the pectoral region) in an attempt to regulate the contractions of the right and left ventricles.

In addition to conventional wired pacing systems, one type of pacing system being developed includes wireless operation. For example, some pacing systems may use wireless electrodes that are attached to the outer epicardial surface of the heart (external to the heart chambers) or embedded in a cardiac vein (external to the heart chambers) to stimulate heart tissue.

SUMMARY

Some embodiments of an electrical stimulation system employ wireless electrode assemblies to provide pacing therapy, defibrillation therapy, or other stimulation therapy. The wireless electrode assemblies may receive energy via an inductive coupling with another device outside the heart (e.g., implanted adjacent to one or more ribs) so as to provide electrical stimulation to the nearby heart tissue. In certain embodiments, the wireless electrode assemblies may include a guide wire channel so that each electrode assembly can be advanced over a guide wire instrument through the endocardium. For example, a distal tip portion of a guide wire instrument can penetrate through the endocardium and into the myocardial wall of a heart chamber, and the electrode assembly may then be advanced over the guide wire and into the heart chamber wall. In such circumstances, the guide wire instrument (and other portions of the delivery system) can be retracted from the heart chamber wall, thereby leaving the electrode assembly embedded in the heart tissue.

Some embodiments include an electrode delivery system for delivering a wireless electrode assembly into a heart chamber wall. The system may include a wireless electrode assembly including a body that defines a guide wire channel extending therethrough. The system may also include a delivery catheter to direct the wireless electrode assembly through a heart chamber and toward a heart chamber wall. The delivery catheter may have a distal opening through which the wireless electrode assembly is passable for delivery into the heart chamber wall. The system may further include a guide wire instrument passable through the delivery catheter to penetrate into the heart chamber wall. The guide wire instrument may have a distal tip portion that is slidable within the guide wire channel of the wireless electrode assembly when the wireless electrode assembly is advanced over the guide wire instrument into the heart chamber wall.

In particular embodiments, an electrode delivery system for delivering a wireless electrode assembly may include a delivery catheter to direct a wireless electrode assembly toward a heart chamber wall when the electrode assembly is disposed therein. The delivery catheter may have a distal opening through which the wireless electrode assembly is passable. The system may also include an actuation member to push the electrode assembly out of the distal opening of the delivery catheter and into the heart chamber wall. The actuation member may be movably adjustable within the delivery catheter. Further, the system may include a guide wire instrument passable through the delivery catheter and having a distal tip portion to define a penetration path through endocardium tissue and into myocardium tissue of the heart wall chamber. When the actuation member pushes the electrode assembly out of the distal opening of the delivery catheter, the electrode assembly advances over the distal tip portion of the guide wire instrument to implant into the myocardium tissue along the penetration path.

In some embodiments, a wireless electrode assembly for electrical stimulation of heart tissue may include a body portion at least partially containing a circuit to deliver electrical stimulation from an electrode surface. The assembly may also include a tissue penetration surface along the body portion to initiate penetration of the body portion into a heart chamber wall. The assembly may further include a guide wire channel defined by the body portion and extending in a longitudinal direction through the body portion toward the tissue penetration surface.

Some embodiments include a method for delivering a wireless electrode assembly into a heart chamber wall. The method may include directing a distal portion of a delivery catheter into a heart chamber, and advancing a guide wire instrument out of the distal portion of the delivery catheter to penetrate a distal tip portion of guide wire instrument into a heart chamber wall. The method may also include advancing a wireless electrode assembly out of the distal portion of the delivery catheter and over the distal tip portion of the guide wire instrument to implant the electrode assembly in the heart chamber wall.

Some of the embodiments described herein may have one or more of the following advantages. First, the delivery system may include a guide wire instrument that initiates penetration of the heart chamber wall, thereby facilitating the subsequent penetration by the electrode assembly. Second, the guide wire instrument may include one or more sensor electrodes to sense local electrical activity (e.g., an electrogram or the like) and to transmit a test stimulation signal (e.g., a pacing signal) at the proposed implantation site. Third, the delivery system may be configured to advance the electrode assembly in a controlled manner to a selected insertion depth into the heart wall tissue. Fourth, the delivery system may include a magnetic coupling device that releasably retains the electrode assembly in a delivery catheter. Fifth, the delivery system may include a guide wire instrument that is configured to guide the electrode assembly into the heart wall tissue along a curved insertion path, thereby permitting the electrode assembly to be embedded between selected tissue fibers. Sixth, the delivery system may include a guide wire instrument having one or more fixation devices extending therefrom so as to secure the guide wire instrument to the heart wall tissue and maintain the guide wire position during the implantation process. Seventh, the delivery system may include a guide wire instrument having a detachable tip portion that serves to reduce migration and to maintain the orientation of the electrode assembly implanted in the heart wall tissue. Eighth, the delivery system may include a delivery catheter that is releasably attachable to the heart chamber wall so as to maintain the position of the delivery catheter during the implantation process.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a section view of a heart and at least a portion of an electrode delivery system, in accordance with some embodiments.

FIG. 2 is a partial cross-sectional view of the portion of the electrode delivery system of FIG. 1.

FIG. 3 is a perspective view of the electrode delivery system of FIG. 1 and an electrical stimulation system, in accordance with some embodiments.

FIG. 4 is a diagram of a device of the electrical stimulation system of FIG. 3.

FIG. 5 is a circuit diagram of at least a portion of a wireless electrode assembly of the electrical stimulation system of FIG. 3.

FIGS. 6-8 are partial cross-sectional views of an electrode delivery system, in accordance with some embodiments.

FIGS. 9-10 are partial cross-sectional views of another embodiment of an electrode delivery system.

FIGS. 11-15 are perspective views of portions of guide wire instruments, in accordance with some embodiments.

FIG. 16 is a partial cross-sectional view of an electrode delivery system having a detachable guide wire portion, in accordance with some embodiments.

FIG. 17 is a partial cross-sectional view of another embodiment of an electrode delivery system having a detachable guide wire portion.

FIGS. 18-19 are partial cross-sectional views of an electrode delivery system having a detachable anchor portion, in accordance with some embodiments.

FIG. 20 is a partial cross-sectional view of an electrode delivery system having a detachable guide wire portion, in accordance with some embodiments.

FIG. 21 is a side view of a portion of an electrode delivery system, in accordance with some embodiments.

FIGS. 22-25 are views of portion of electrode delivery system, in accordance with some embodiments.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Referring to FIG. 1, an electrode delivery system 100 may be used to introduce one or more wireless electrode assemblies 120 into the heart chamber walls. In this example, there are four wireless electrode assemblies 120 implanted in the heart chamber wall of each of the left atrium 32, the left ventricle 34, the right atrium 36, and the right ventricle 38. As described below in connection with FIGS. 3-5, the wireless electrode assemblies 120 may be part of an electrical stimulation system 20 that wirelessly transmits energy to the electrode assemblies 120 for electrical stimulation of the surrounding heart wall tissue 35. The electrode delivery system 100 includes a delivery catheter 130 with a distal opening and a guide wire instrument 140 that is passable through the delivery catheter 130. The guide wire instrument 140 is capable of penetrating into a heart chamber wall, as shown in FIG. 1. After penetration, an electrode assembly 120 is advanced in a distal direction over at least a portion of the guide wire instrument 140 so that the electrode assembly 120 is implanted entirely within the heart chamber wall, as shown in FIG. 1. Exemplary embodiments of the proximal portions of the delivery catheter 130 and the guide wire 140 extending outside the patient's body are shown and described below in connection with FIG. 3.

In more detail, the delivery system 100 shown in FIG. 1 includes a guide sheath 110 that is capable of being directed (e.g., by a surgeon or other user) through one or more veins or arteries to the targeted chamber of the heart 30 (e.g., the left ventricle 34 is the targeted chamber in the embodiment shown in FIG. 1). For example, in those embodiments in which the atrial septum or a heart valve is to be crossed during the delivery procedure, the guide sheath 110 can maintain such a crossing while a plurality of electrode assemblies 120 are directed therethrough into the targeted heart chamber. For example, in the embodiment shown in FIG. 1, the guide sheath 110 maintains a crossing through the atrial septum (e.g., entering through the right atrium 36, passing through the atrial septum, and passing into the left atrium 32) and maintain a crossing through the left mitral valve (e.g., passing through the left mitral valve, and passing into the left ventricle 34). In an alternative example, the guide sheath 110 can be directed through a femoral artery, around the aortic arch, and into the left ventricle 34.

After the guide sheath 110 is deployed into the targeted heart chamber, multiple wireless electrode assemblies 120 may be consecutively delivered through the guide sheath 110 using at least one delivery catheter 130. The multiple assemblies 120 may be delivered without having to remove the outer sheath 110, thereby reducing the delivery time and reducing the likelihood of trauma to the atrial septum or heart valve crossing due to repeated insertions.

Still referring to FIG. 1, the guide wire instrument 140 has a distal tip adapted to penetrate through the endocardium 33 and into the heart wall tissue 35 (e.g., tissue such as the myocardial wall) before the electrode assembly 120 is advanced into the heart wall tissue 35. As such, the guide wire instrument 140 may initiate a penetration path into the heart chamber wall, thereby facilitating the subsequent penetration by the electrode assembly 120 along the penetration path. For example, in the embodiment depicted in FIG. 1, the distal tip portion 142 of the guide wire instrument 140 can penetrate through the endocardium 33 and into the heart wall tissue 35, thereby forming an opening in the endocardium 33. Then the electrode assembly 120 can be advanced over the distal tip portion 142 to further dilate opening in the endocardium 33 (which was previously formed by the guide wire instrument 140) and to penetrate into the heart wall tissue 35.

In addition, the guide wire instrument 140 may include at least one sensor electrode 144 (FIG. 2) along its distal tip portion 142 that is configured to sense local electrical activity (e.g., an electrogram or the like) and to transmit a test stimulation signal (e.g., a pacing signal) after initiating the penetration into the implantation site. In these circumstances, the guide wire instrument 140 may be used to determine if the implantation site is suitable for receipt of an electrode assembly 120 before the electrode assembly 120 is advanced into the heart wall tissue 35. For example, the guide wire instrument 140 may comprise a conductive electrical line extending from the sensor electrode 144 (FIG. 2) along the distal tip portion 142 to the proximal portion 148 (FIG. 3) of the guide wire instrument 140 (e.g., outside the patient's body). In these circumstances, the guide wire instrument 140 may be connected to an electrogram or ECG monitor system or the like so that a physician may view the local electrical activity in the heart wall tissue 35 into which the distal tip portion 142 has penetrated. Further, a pulse generator device or the like may be electrically connected to the proximal portion 148 (FIG. 3) of the guide wire instrument 140 (e.g., outside the patient's body) so as to transmit test pacing signals to heart wall tissue 35 adjacent to the distal tip portion 142. In some circumstances, the sensor electrode 144 may comprise a marker material that permits viewability of the guide wire instrument 140 in the heart 30 using medical imaging techniques. In addition or in the alternative, at least the distal tip portion 142 of the guide wire instrument 140 may comprise a marker material or a marker band (not shown) to permit viewability of the guide wire instrument 140 in the heart 30 using medical imaging techniques.

FIG. 2 shows a more detailed view of the distal portion of the embodiments of the delivery system 100 and the wireless electrode assembly 120 previously described in connection with FIG. 1. The electrode assembly 120, in this example, includes a guide wire channel 122 through which at least a distal tip portion 142 of the guide wire instrument 140 extends. A movable engagement between the electrode assembly 120 and the guide wire instrument 140 (e.g., a slidable engagement) permits the electrode assembly 120 to be advanced over the guide wire instrument 140 into the heart wall tissue 35 and permits the guide wire instrument 140 (and other portions of the delivery system 100) to be retracted from the electrode assembly 120 after implantation is completed. In this embodiment, the electrode assembly 120 also includes a body portion 125 that at least partially contains a circuit (described in more detail below in connection with FIG. 5) to deliver electrical stimulation from one or more electrode surfaces 124 and 126. For example, in those embodiments in which the electrode assembly 120 provides bipolar functionality, the electrode assembly 120 may include a first electrode 124 disposed opposite a second electrode 126 so as to provide a stimulation circuit from one electrode (e.g., the second electrode 126), through the surrounding heart wall tissue 35, and to the other electrode (e.g., the first electrode 124). As shown in FIG. 2, the first and second electrodes 124 and 126 may be disposed along an outer surface of the body portion 125 so as to contact the heart wall tissue 35 when implanted therein. The electrode assembly 120 may also include a tissue penetration surface 127 along the body portion 125 to facilitate penetration of the body portion 125 into the heart wall tissue 35. For example, the tissue penetration surface 127 has a generally conical shape or other distally narrowing shape to facilitate the insertion process. In the embodiment depicted in FIG. 2, the distal electrode 126 extends along the conical surface of the tissue penetration surface 127. The guide wire channel 122 may extend in a substantially longitudinal direction through the body portion 125 toward the tissue penetration surface 127 so that the tissue penetration surface 127 can be advanced in the direction of the previously inserted guide wire instrument 140. As previously described, in this embodiment, the guide wire instrument 140 includes at least one sensor electrode 144 disposed along the distal tip portion 142 to sense local electrical activity (e.g., an electrogram or the like) and to transmit a test stimulation signal (e.g., a pacing signal).

In some embodiments, the wireless electrode assemblies 120 may be sized to be implanted entirely within a heart chamber wall, which can have a wall thickness of about 3 mm to about 30 mm and more specifically about 5 mm to about 25 mm for ventricle walls, and about 1 mm to about 5 mm and more specifically about 2 mm to about 4 mm for atrial walls. Also in these embodiments, the wireless electrode assemblies 120 are sized to slidably receive at least the distal tip portion 142 of the guide wire instrument 140, which can have an outer diameter of about 0.1 mm to about 1.0 mm, about 0.2 mm to about 0.8 mm, and more specifically about 0.25 mm to about 0.5 mm. Accordingly, in such embodiments, the body portion 125 of the electrode assembly 120 may have a longitudinal length of about 20 mm or less, about 15 mm or less, about 10 mm or less, for example, about 3 mm to about 10 mm, and in some circumstances (e.g., implantation in the atrial wall) about 5 mm or less, for example about 3 mm to about 5 mm. Also, in these embodiments, the body portion 125 may have a generally circular cross-sectional shape with a maximum outer diameter of about 0.5 mm to about 3.5 mm, about 1 mm to about 3 mm, and more specifically about 1.5 mm to about 2.5 mm. Further, in some embodiments, the guide wire channel 122 may have a diameter of about 0.15 mm to about 1.05 mm, about 0.25 mm to about 0.85 mm, and about 0.30 mm to about 0.55 mm so as to accommodate the guide wire instrument 140 having a diameter as previously described.

Still referring to FIG. 2, the electrode assembly 120 may be releasably retained in the distal portion 134 of the delivery catheter 130 during advancement through the guide sheath 110. In this embodiment, a magnetic coupling device 150 is disposed in the distal portion 134 of the delivery catheter 130 so as to releasably retain the electrode assembly 120 in a non-deployed position (not shown in FIG. 2). For example, the magnetic coupling device 150 may include one or more ring magnets axially aligned with the distal portion 134 of the delivery catheter 130 so that a distal surface 158 of the magnetic coupling device 150 is magnetically attracted to an opposing surface 128 of the electrode assembly 120. In this embodiment, the magnetic coupling device 150 comprises rare earth magnets and the proximal surface 128 of the electrode assembly 120 may comprise a magnetically attractable metal material, such as stainless steel or the like. In some circumstances, the magnetic coupling device 150 disposed in the distal portion 134 of the delivery catheter 130 may aid in controlled-delivery of the delivery catheter through the patient's body and into the targeted heart chamber. For example, the magnetic coupling device 150 in the distal portion of the delivery catheter 130 can be directed through the patient's venous or arterial system using a magnetic navigation system, in which two or more large magnets outside the patient's body are arranged to generate magnetic fields that direct the distal portion 134 of the catheter 130 I the desired direction. One example of such a magnetic navigation system supplied by Stereotaxis, Inc. of St. Louis, Mo.

Alternatively, the magnetic coupling device 150 comprises a coil of wire wound around a permeable core such as iron or ferrite, so that when current flows through said coil, device 150 is magnetically attracted to proximal surface 128, and when the coil current is switched off, device 150 releases from proximal surface 128. The current in said coil may be either direct or alternating current (DC or AC). In those embodiments in which the current for providing electromagnetic attraction to proximal surface 128 is AC, the magnetic coupling device 150 may provide a magnetic field that inductively couples with the coil in the electrode assembly 120 to provide a supplemental recharge to the electrode assembly 120 during the delivery process. Such a supplemental recharge from the magnetic coupling device 150 may ensure that there is sufficient energy stored for a test stimulation pulse (described in more detail below in connection with FIGS. 6-8) between the electrodes 124 and 126 during the implantation of the electrode assembly 120 (e.g., to verify the operation of the electrode assembly in the implantation site).

It should be understood that, in other embodiments, the electrode assembly 120 may be releasably retained in the delivery catheter 130 using a friction-fit engagement, a mechanical connection (e.g., a threaded engagement, a mating slot and groove engagement, etc.), or the like.

As shown in FIG. 2, an actuation member 160 may be adjusted within the delivery catheter 130 to release the electrode assembly 120 from the distal portion 134 of the delivery catheter 130. For example, after the delivery catheter 130 is directed to a position adjacent to a targeted heart chamber wall, the actuation member 160 may be adjusted to force the electrode assembly 120 away from the magnetic coupling device 150 and into the heart wall tissue 35 that was previously penetrated by the guide wire instrument 140. In this embodiment, the actuation member 160 serves as an adjustable push rod that can shift from a retracted configuration to an extended configuration so as to advance the electrode assembly 120 to a deployed position outside the distal opening 135 of the delivery catheter 130. The actuation member 160 may comprise a flexible main shaft 163 that can transmit a pushing force applied from the proximal end (e.g., outside the patient's body) to a distal section 162. As described in more detail below in connection with FIG. 3, a surgeon or other user can actuate a hand-operated trigger device 137 or the like disposed along the proximal portion 138 of the delivery catheter 130 to apply the pushing force to the actuation member 160 and thereby adjust the position of the distal section 162. The distal section 162 may have a reduced diameter that is advanced through a centering mechanism 154 so as to abut the proximal surface 128 of the electrode assembly 120 during advancement of the electrode assembly 120 over the guide wire instrument 140. The distal section 162 may transition to the reduced diameter at a shoulder 164, which is configured to abut the centering mechanism 154 when the actuation member 160 has been advanced to a predetermined extension distance (refer, for example, to distance L in FIG. 6). As such, the actuation member 160 may be used to advance the electrode assembly 120 to a selected depth into the hearth wall tissue 35, and such advancement may cease when the shoulder 164 of the actuation member 160 abuts with the centering mechanism 154. Accordingly, the heart wall tissue 35 can be protected from over advancement of the electrode assembly, which could result in the electrode assembly 120 being forced entirely through the heart wall.

In an alternative embodiment, the magnetic coupling device 150 and the centering mechanism 154 may be incorporated onto the main shaft 163 of the actuation member 160. In such circumstances, the distal section 162 would be an inner push rod shaft that extends fully through the main shaft of the actuation member 160. Thus, the actuation member 160, the magnetic coupling 150, and the electrode assembly 120 may be inserted into a proximal portion 138 of the delivery catheter 130 (e.g., outside the patient's body as shown in FIG. 3) and directed through the delivery catheter 130 to the targeted implantation site. In these embodiments, when the electrode assembly 120 is to be released from the magnetic coupling device 150, the distal section 162 can be moved distally relative to the main shaft 163.

Referring to FIGS. 2-3 (showing the distal portion and proximal portion of the delivery system 100, respectively), during a surgical process conducted by a surgeon or other user, the electrode assembly 120 may be disposed in the delivery catheter 130 and advanced through the guide sheath 110 toward the targeted heart chamber 32, 34, 36, or 38. As shown in FIG. 3, the guide sheath 110 may be introduced via an incision in the patient's neck and advanced through the venous system to the heart 30 (e.g., though the superior vena cava, through the right atrium 36, crossing through the atrial septum, through the left atrium 32, and into the left ventricle 34). As shown in FIG. 2, the guide sheath 110 may be configured to slidably receive the delivery catheter 130 so that the electrode assembly 120 may be loaded into the delivery catheter 130 outside the patient's body and then directed through the guide sheath 110 to the heart 30. For example, before the distal end of the delivery catheter 130 is inserted into the proximal portion 118 of the guide sheath 110 (refer to FIG. 3 for an exemplary embodiment of the proximal portion 118), the user may insert the electrode assembly 120 into the distal opening 135 of the delivery catheter 130 and force the electrode assembly 120 toward a releasably retainer device (e.g., the magnetic coupling device 150 as described in connection with FIG. 2). Then the delivery catheter 130 (with the electrode assembly 120 retained therein) can be inserted into the proximal portion 118 of the guide sheath 110 and directed therethrough to the targeted heart chamber. The user can insert the guide wire instrument 140 into the proximal portion 138 of the delivery catheter 130 (refer to FIG. 3 for an exemplary embodiment of the proximal portion 138) and advance the guide wire instrument 140 therethrough to penetrate the targeted tissue site within the targeted heart chamber. As shown in FIG. 3, the surgeon or other user may operate the trigger device 137 along the proximal portion of the delivery catheter 130 to adjust the distal section 162 of the actuation member 160 (FIG. 2). The actuation member 160 forces the electrode assembly 120 to deployed out of the distal opening 135 of the delivery catheter 130 and over the distal tip portion 142 for implantation into the heart wall tissue 35. After the electrode assembly 120 is implanted in the heart wall tissue 35, the delivery catheter 130 and the guide wire instrument 140 may be withdrawn from the proximal portion 118 of the guide sheath 110 (e.g., withdrawn fully outside of the patient's body), while the guide sheath 110 remains in the patient's body, for example, to maintain the delivery path into the targeted heart chamber. If a subsequent electrode assembly is to be delivery to the same heart chamber, a new electrode assembly 120 may be loaded into the distal opening 135 of same delivery catheter 130 (or into a new delivery catheter 130 having a similar construction) for delivery through the guide sheath 110 to a new implantation site along the targeted heart chamber wall.

In these embodiments, the guide sheath 110 can include a steering mechanism (not shown in FIGS. 2-3), such as steering wires, shape memory device, or the like, to shift the distal end during advancement into the targeted heart chamber and optionally includes at least one marker band 112 (FIG. 2) to permit viewability of the distal end of the guide sheath 110 in the patient's body using medical imaging techniques. Such a marker band 112 may aid a physician when steering the guide sheath 110 to the targeted heart chamber. Likewise, the delivery catheter 130 may also include a steering mechanism (not shown in FIGS. 2-3) so as to adjust its distal end during advance to a position adjacent the heart chamber wall and may also include at least one marker band 132 (FIG. 2) to permit viewability of the distal end of the delivery catheter 130 in the patient's body using medical imaging techniques.

Referring now to the operation of the electrical stimulation system 20 as shown, for example, in FIGS. 3-5, the wireless electrode assemblies 120 may be part of an electrical stimulation system 20 that wirelessly transmits energy to the electrode assemblies 120 for electrical stimulation of the surrounding heart wall tissue 35. As described in more detail below in connection with FIG. 5, each of the wireless electrode assemblies 120 may have an internal coil that is inductively coupled with an external power source coil to charge an electrical charge storage device (e.g., a capacitor or a battery) contained within the wireless electrode assembly 120. Also as described in more detail below, each of the wireless electrode assemblies 120 may have control circuitry or a triggering mechanism to deliver stored electrical charge to adjacent heart tissue. In alternative embodiments, one or more of the wireless electrode assemblies 120 has no energy storage device, such as a battery or capacitor. In these alternative embodiments, each wireless electrode assembly may comprise, for example, of a ferrite core and ring electrodes (e.g., bipolar electrodes) encircling the ends of the core. A number of turns of fine insulated wire may be coiled around the central portion of the core so as to receive energy from a magnetic field produced by a shaped driving signal, which causes the an stimulation pulse to pass from the coil and to the bipolar electrodes for electrical stimulation of the surrounding heart tissue.

Referring to FIG. 3, the electrical stimulation system 20 may include a stimulation controller 40 (e.g., a pacing controller) and a transmitter 50 that drives an antenna 60 for communication with the wireless electrode assemblies 120. The stimulation controller 40 can include circuitry to sense and analyze the heart's electrical activity, and to determine if and when a stimulation electrical pulse needs to be delivered and by which of the wireless electrode assemblies 120. The sensing capability may be made possible by having sensor electrodes included within the physical assembly of the stimulation controller 40. Alternatively, a single or dual lead pacemaker 90 may sense the local cardiac electrogram and transmit this information to the antenna 60 for use by the controller 40 in determining the timing of wireless electrode assembly 120 firing. In either case, the wireless electrode assembly 120 need not be provided with sensing capability, and also the wireless electrode assemblies 120 need not be equipped with the capability of communicating to the stimulation controller 40 (for example, to communicate information about sensed electrical events). In alternative embodiments, the wireless electrode assemblies 120 include local sensor circuitry to sense the local electrical activity, such as an electrogram. In these alternative embodiments, the local sensor circuitry would communicate with programmable control circuitry in the wireless electrode assembly, which would wirelessly communicate the sensed information to the controller 40 or to another implanted electrode assembly 120.

The transmitter 50—which can be in communication with, and controlled by, the stimulation controller 40—may drive an RF signal onto the antenna 60. In one embodiment, the transmitter 50 provides both (1) a charging signal to charge the electrical charge storage devices (e.g., rechargeable battery, capacitor, or the like) contained within the wireless electrode assemblies 120 via inductive coupling, and (2) an information signal, such as a pacing trigger signal, that is communicated to a selected one or more of the wireless electrode assemblies 120, commanding the selected wireless electrode assembly 120 to deliver its stored charge to the adjacent tissue. The magnetic field transmitted from the antenna 60 may be used to inductively couple with a coil in each of the electrode assemblies 120.

Still referring to FIG. 3, the stimulation controller 40 and the transmitter 50 may be housed in a single enclosure that is implantable within a patient. In such a configuration, the single enclosure device 25 may have a single energy source (e.g., battery) that may be either rechargeable or non-rechargeable. For example, as shown in FIG. 3, the stimulation controller 40 and the transmitter 50 are housed in an enclosure device 25 that is implantable along or along one or more ribs proximate to the heart 30. Such proximity between the antenna 60 and the heart 30 may facilitate efficient inductive coupling between the implanted antenna device 60 and the wireless electrode assemblies 120 embedded in the heart wall tissue 35. Accordingly, in this embodiment, the controller 40 and transmitter 50 are housed in the device 25 that is shaped generally elongate and slightly curved so that it may be anchored between two ribs of the patient, or possibly around one or more ribs. In one example, the housing for the controller 40 and transmitter 50 can be about 2 to 20 cm long and about 1 to 5 cm in diameter, or more specifically, can be about 5 to 10 cm long and about 1 to 2 cm in diameter. Also in this example, this rib-mounted housing may have a non-uniform cross-sectional shape to conform to the ribs and may be curved along its length. Such a shape of the housing for the controller 40 and transmitter 50, which allows the device to be anchored on the ribs, may provide an enclosure that is larger than conventional pacemakers, thereby providing more space for a larger battery having more stored energy. In some embodiments, the controller 40 may comprise a defibrillator circuit that discharges energy to the heart 30 through electrodes on opposing ends of the body of controller housing 25 when fibrillation is sensed. Other sizes and configurations may also be employed as is practical.

In some embodiments, the antenna 60 may be a loop antenna comprised of a long wire that is electrically connected across an electronic circuit contained within the controller/transmitter housing device 25. The electronic circuit delivers pulses of RF current to the antenna 60, generating a magnetic field in the space around the antenna 60 to charge the wireless electrode assemblies 120, as well as RF control magnetic field signals to command the wireless electrode assemblies 120 to discharge. In such embodiments, the antenna 60 may comprise a flexible conductive material so that it may be manipulated by a physician during implantation into a configuration that achieves optimum inductive coupling between the antenna 60 and the coils within the implanted wireless electrode assemblies 120. In one example, the loop antenna 60 may be about 2 to 22 cm long and about 1 to 11 cm wide, and may be about 5 to 11 cm long and about 3 to 7 cm wide. Placement of the antenna 60 over the ribs may provide a relatively large antenna to be constructed that has improved efficiency in coupling RF energy to the pacing wireless electrode assemblies 120.

In an alternative configuration, the stimulation controller 40 and the transmitter 50 may be physically separate components. As an example of such a configuration, the stimulation controller 50 may be implantable, for example in the pacemaker configuration, whereas the transmitter 50 (along with the antenna 60) may be adapted to be worn externally, such as in a harness that is worn by the patient. In the latter example, the stimulation controller 40 would have its own energy source (e.g., battery), and that energy need not be rechargeable given the relatively small energy requirements of the stimulation controller 40 as compared to the energy requirements of the transmitter 50 to be able to electrically charge the wireless electrode assemblies 120. In this case, the stimulation controller 40 would sense the local electrogram signal through a wired pacing lead, and transmit the sensed information to the external controller. Again, transmission of information, as opposed to pacing energy, has a relatively low power requirement, so a pacemaker enclosure and battery may suffice.

In some embodiments, an external programmer 70 is used to communicate with the stimulation controller 40, including after the stimulation controller 40 has been implanted. The external programmer 70 may be used to program such parameters as the timing of stimulation pulses in relation to certain sensed electrical activity of the heart, the energy level of stimulation pulses, the duration of stimulation pulse (that is, pulse width), etc. The programmer 70 includes an antenna 75 to communicate with the stimulation controller 40, using, for example, RF signals. The implantable stimulation controller 40 is accordingly equipped to communicate with the external programmer 70, using, for example, RF signals. The antenna 60 may be used to provide such communications, or alternatively, the stimulation controller 40 may have an additional antenna (not shown in FIG. 3) for external communications with the programmer 70, and in an embodiment where the transmitter 50 and antenna 60 are housed separately from the controller 40, for communications with the transmitter 50.

As shown in FIG. 3, some embodiments of the system 20 may also include a pacemaker/defibrillator device 90 and associated wired leads 95 which extend from the pacemaker/defibrillator device 90 and into one or more chambers of the heart 30. For example, the system 20 may include wired leads 95 from the pacemaker/defibrillator 90 that extend into the right atrium 36 and the right ventricle 38 while wireless electrode assemblies are disposed in the left atrium 32 and the left ventricle 34. The pacemaker/defibrillator 90 may be used to sense the internal electrogram or ECG signals, to deliver defibrillation shocks, and to communicate with the controller 40 and/or transmitter 50 as previously described.

One parameter of the wireless electrode assembly 120 that may be a factor in the design of the electrical stimulation system 20 is the stimulation energy required to pace or otherwise stimulate the ventricles 34 and 38 or other chamber of the heart 30. This energy requirement can include a typical value needed to pace ventricular myocardium, but also can include a margin to account for degradation of contact between the electrodes and tissue over time. In certain embodiments, each wireless electrode assembly 120 may require the maximum pacing threshold energy. This threshold energy is supplied to the wireless electrode assemblies between heartbeats by an external radio frequency generator (which may also be implanted), or other suitable energy source that may be implanted within the body or from a rechargeable battery contained within electrode assembly 120. In some circumstances, parameter values for some embodiments may be:

- Threshold pacing voltage=2.5 Volts
- Approximate tissue impedance=600 Ohms
- Approximate pulse duration=0.4 mSec
- Derived threshold energy=4 micro-Joules

Because RF fields at frequencies higher than about 200 kHz may be attenuated by the body's electrical conductivity, and because electric fields of any frequency may be attenuated within the body, energy transmission through the body may be accomplished in some embodiments via a magnetic field at about 20-200 kHz (or by a magnetic field pulse that contains major frequency components in this range), and more particularly by transmission of magnetic fields in the range of 100-200 kHz when transmission is through relatively conductive blood and heart muscle.

In some embodiments, each of the wireless electrode assemblies 120 includes a rechargeable battery. This battery may provide power for delivering pacing energy to the tissue, and for operating communications, logic, and memory circuitry contained within the assembly. In such embodiments, the transmitter 50 and the antenna 60 (FIG. 3) may be external to the patient, and may serve to recharge the batteries within the electrode assemblies. The recharge transmitter and antenna may be incorporated into furniture, incorporated into the patient's bed, or worn by the patient (e.g., in a vest-type garment). Daily recharging for predetermined periods (e.g., about 30 minutes) may be required. In these circumstances, the wireless electrode assemblies 120 may be autonomous pacing devices, which can sense the local electrogram and only pace when the local tissue is not refractory. Such electrodes may communicate with the programming unit 70 to receive pacing instructions and transmit data stored in local memory. In these embodiments, each wireless electrode assembly 120 may also communicate with other implanted wireless electrode assemblies 120. For example, one electrode assembly 120 in the right atrium may be designated as the “master,” and all other implanted electrodes are “slaves” that pace with pre-programmed delays relative to the “master.” As such, a master electrode in the right atrium may only sense the heart's sinus rhythm, and may trigger pacing of the slaves with programmed delays.

Referring to FIG. 4, an embodiment of an implantable device 25 (e.g., the rib-implanted configuration shown in FIG. 3) including the controller 40, transmitter 50, and associated antenna 60 is shown in block diagram form. Included within the device 25 is: a battery 26, which may be recharged by receiving RF energy from a source outside the body via antenna 60; ECG sensing electrodes 27 and associated sensing circuitry 28; transmitter circuitry 50 for transmitting RF energy and firing commands to the implanted wireless electrode assemblies, transmitting status information to the external programmer, receiving control instructions from the external programmer, and receiving power to recharge the battery; and a stimulation controller 40 that is programmed to control the overall functioning of the implantable device 25. In alternative embodiments, antenna 60 may receive signals from the individual wireless electrode assemblies 120 containing information regarding the local electrogram at the site of each wireless electrode assembly, and/or the antenna 60 may receive signals from an implanted pacemaker device 90 regarding the electrogram signal at the sites of one or more conventional leads implanted on the right side of the heart.

Referring to FIG. 5, some embodiments of a wireless electrode assembly 120 may include a receiver coil 172 that is capable of being inductively coupled to a magnetic field source generating a time-varying magnetic field at the location of coil 172, such as would be generated by the transmitter 50 and the antenna 60 depicted in FIG. 3. The RF current in the external antenna may be a pulsed alternating current (AC) or a pulsed DC current, and thus the current induced through the receiver coil 172 may likewise be an AC or pulsed DC current. The current induced in coil 172 may be proportional to the time rate of change of the magnetic field generated at the site of coil 172 by the external RF current source. In some embodiments, a four-diode bridge rectifier 173 may connected across the receiver coil 172 to rectify the AC or pulsed DC current that is induced in the receiver coil 172. A three-position switch device 174 may be connected so that when the switch device 174 is in a first position, the rectifier 173 produces a rectified output that is imposed across a capacitor 175 or other power storage device. As such, when the switch device 174 is in the position 1 (as is the case in FIG. 5), the capacitor 175 stores the induced electrical energy.

The switch device 174, in this example, can be a voltage-controlled device that is connected to sense a voltage across the capacitor 175 to determine when the capacitor 175 has been sufficiently charged to a specified pacing threshold voltage level. When the capacitor 175 is sensed to have reached the specified pacing threshold level, the voltage-controlled switch device 174 moves to a position 2, which disconnects the capacitor 175 from the coil 172. With the switch device 174 in the position 2, the capacitor 175 is electrically isolated and remains charged, and thus is ready to be discharged. The voltage controlled switch device 174 may comprise a solid state switch, such as a field effect transistor, with its gate connected to the output of a voltage comparator that compares the voltage on capacitor 175 to a reference voltage. The reference voltage may be set at the factory, or adjusted remotely (e.g., after being implanted) via signals sent from the physician programmer unit 70 (FIG. 3), received by coil 172 and processed by circuitry not shown in FIG. 5. The electronic circuitry contained within the wireless electrode assembly 120, including the voltage controlled switch 174, can be constructed with components that consume very little power, for example CMOS. Power for such circuitry is either taken from a micro-battery contained within the wireless electrode assembly, or supplied by draining a small amount of charge from capacitor 175.

Still referring to FIG. 5, a narrow band pass filter device 176 may also be connected across the receiver coil 172, as well as being connected to the three-position switch device 174. The band pass filter device 176 passes only a single frequency of communication signal that is induced in the coil 172. The single frequency of the communication signal that is passed by the filter device 176 may be unique for the particular wireless electrode assembly 120 as compared to other implanted wireless electrode assemblies. When the receiver coil 172 receives a short magnetic field burst at this particular frequency, the filter device 176 passes the voltage to the switch device 174, which in turn moves to a position 3. With the switch device 174 in the position 3, the capacitor 175 may be connected in series through the previously described electrodes 124 and 126 (refer also to FIG. 2), to the tissue to be stimulated. As such, at least some of the charge that is stored on the capacitor 175 is discharged through the tissue (e.g., heart wall tissue 35). When this happens, the tissue becomes electrically depolarized. In one example embodiment described in more detail below, the bipolar electrodes 124 and 126 across which stimulation pulses are provided are physically located at opposite ends (e.g., a proximal end and a distal end) of the wireless electrode assembly 120. After a predetermined, or programmed, period of time, the switch returns to position 1 so the capacitor 175 may be charged back up to the selected threshold level.

It should be noted that, for sake of clarity, the schematic diagram of FIG. 5 shows only the electrical components for energy storage and for switching, in accordance with particular embodiments of the wireless electrode assembly 120. Not necessarily shown are electronics to condition the stimulation pulse delivered to the tissues, which circuitry should be understood from the description herein. Some aspects of the pulse, for example pulse width and amplitude, may be remotely programmable via encoded signals received through the filter device 176 of the wireless electrode assembly 120. In this regard, filter 176 may be a simple band pass filter with a frequency unique to a particular wireless electrode assembly, and the incoming signal may be modulated with programming information. Alternatively, filter 176 may consist of any type of demodulator or decoder that receives analog or digital information induced by the external source in coil 172. The received information may contain a code unique to each wireless electrode assembly to command discharge of capacitor 175, along with more elaborate instructions controlling discharge parameters such as threshold voltage for firing, duration and shape of the discharge pulse, etc.

Using wireless electrode assemblies 120 of the type shown in FIG. 5, all of the implanted wireless electrode assemblies 120 may be charged simultaneously by a single burst of an RF charging field from a transmitter antenna 60. Because back reaction of the wireless electrode assemblies 120 on the antenna 60 may be small, transmitter 50 (FIG. 3) losses may be primarily due to Ohmic heating of the transmit antenna 60 during the transmit burst, Ohmic heating of the receive coil 122, and Ohmic heating of conductive body tissues by eddy currents induced in these tissues by the applied RF magnetic field. By way of comparison, if eight wireless electrode assemblies 120 are implanted and each is addressed independently for charging, the transmitter 50 may be turned ON eight times as long, which may require almost eight times more energy, the additional energy being primarily lost in heating of the transmit antenna 60 and conductive body tissues. With the wireless electrode assembly 120 of FIG. 5, however, all implanted wireless electrode assemblies can be charged simultaneously with a burst of RF current in antenna 60, and antenna and body tissue heating occurs only during the time required for this single short burst. Each wireless electrode assembly 120 is addressed independently through its filter device 176 to trigger pacing. The transmitted trigger fields can be of much smaller amplitude, and therefore lose much less energy to Ohmic heating, than the transmitted charging pulse.

Referring now to the process of delivering the wireless electrode assemblies 120 to the heart wall tissue 35 as shown in FIGS. 6-8, the electrode delivery system 100 may be operated to initially penetrate the heart wall tissue 35 with the guide wire instrument 140 before advancing the electrode assembly 120 into the tissue 35. Such initial penetration by the guide wire instrument 140 can facilitate the subsequent penetration by the electrode assembly 120. As shown in FIG. 6, the guide sheath 110 is shown within a targeted heart chamber, and the delivery catheter 130 may be advanced to an implantation site along the endocardium 33. As previously described in connection with FIGS. 2-3, the guide sheath 110 may be introduced via an incision in the patient's neck and advanced through the venous system to the heart 30 (e.g., though the superior vena cava and into the heart 30) or via an incision in the patient's leg and advanced through one or more arteries to the heart 30 (e.g., through the femoral artery, around the aortic arch, and into the heart 30). Also as previously described, the delivery catheter 130 can be directed through the guide sheath 110 to the targeted heart chamber. The magnetic coupling device 150 may releasably retain the electrode assembly 120 in the non-deployed position inside the distal portion 134 of the delivery catheter 130. In this embodiment, the distal section 162 of the actuation member 160 is in a retracted position such that the shoulder 164 is separated from the centering mechanism 154 by at least a separation distance L.

Still referring to FIG. 6, when the delivery catheter 130 has been directed to the targeted implantation site along the endocardium 33, the distal tip portion 142 of the guide wire instrument 140 can be advanced distally to penetrate through the endocardium and into the heart wall tissue 35. As previously described, the guide wire instrument 140 may include at least one sensor electrode 144 along its distal tip portion 142 that is configured to sense local electrical activity (e.g., an electrogram or the like) and to transmit a test stimulation signal (e.g., a pacing signal) at the implantation site. In these circumstances, the guide wire instrument 140 may be used to determine if the implantation site is suitable for receipt of an electrode assembly 120 before the electrode assembly 120 is advanced into the heart wall tissue 35. The sensor electrode 144 may be in electrical communication with an electrogram or ECG monitor system (e.g., outside the patient's body) or the like so that a physician may view the local electrical activity in the heart wall tissue 35 into which the distal tip portion 142 has penetrated. Optionally, a pulse generator device or the like may be electrically connected to the proximal portion 148 (FIG. 3) of the guide wire instrument 140 so as to transmit test pacing signals to heart wall tissue 35 proximate to the sensor electrode 144.

Referring to FIG. 7, after the guide wire instrument 140 has penetrated into the heart wall tissue 35, the actuation member 160 may be adjusted so as to force the electrode assembly 120 over the guide wire instrument 140 and into the heart wall tissue 35. As previously in connection with FIGS. 2-3, a surgeon or other user may actuate a hand-operated trigger device 137 (FIG. 3) or the like disposed along the proximal portion 138 of the delivery catheter 130 to adjust the position of the distal section 162 of the actuation member 160. For example, the distal section 162 of the actuation member 162 may abut the proximal surface 128 of the electrode assembly 120 so that the actuation member 160 transmits an insertion force to the electrode assembly 120 (in response to actuation of the trigger device 137 (FIG. 3)). Such an insertion force advances the electrode assembly 120 over the guide wire instrument 140 as the guide wire channel 122 slides over the distal tip portion 142. Also, as previously described, the tissue penetration surface 127 may engage to the heart wall tissue 130 to open the tissue as the electrode assembly 120 is advanced. The actuation member 160 may be pushed forward by a distance L (FIG. 6) before the shoulder 164 abuts the centering mechanism 154. According, the depth of penetration of the electrode assembly 120 is controlled by the limited distance to which the actuation member 160 may be adjusted while advancing the electrode assembly 120. In other embodiments, the depth of penetration of the electrode assembly 120 may be controlled or monitored using stopper devices, depth markings along the trigger device 137 (FIG. 3), or the like. Advancing the electrode assembly 120 into the heart wall tissue 130 in such a controllable manner can reduce the likelihood of forcing the electrode assembly 120 fully through the heart wall.

Referring to FIG. 8, after the electrode assembly 120 is advanced over the guide wire instrument 140 to a selected depth into the heart wall tissue 35, the guide wire instrument 140 and the actuation member 160 may be withdrawn from the tissue 35. The opening in the endocardium 33 through which the actuation member 160 was passed may substantially retract after the actuation member 160 is withdrawn, thereby embedding the electrode assembly 120 in the heart wall tissue 35. In some embodiments, the embedded electrode assembly 120 may be prompted to transmit a test stimulation pulse from the electrode surfaces 124 and 126, which can verify the operability of the electrode assembly 120 in the implantation site. The actuation member 160, the guide wire instrument 140, and the delivery catheter 130 may be retracted from the guide sheath 110 while the guide sheath 110 maintains the delivery path into the targeted heart chamber. As previously described, if a subsequent electrode assembly 120 is to be delivery to the same heart chamber, a new electrode assembly 120 may be loaded into the same delivery catheter 130 (or into a new delivery catheter 130 having a similar construction) for delivery through the guide sheath 110 to a new implantation site along the targeted heart chamber wall. Thus, the subsequent electrode assembly 120 can be delivered to the targeted heart chamber without having to remove the guide sheath 110 from the heart 30, thereby reducing the likelihood of irritation or trauma to the atrial septum, the heart valves, and other heart structures caused by repeated insertions of a sheath or catheter.

Referring now to FIGS. 9-10, in some embodiments, the electrode assembly 120 may be advanced into the heart wall tissue 35 in a direction that is non-perpendicular to the endocardial surface 33. For example, some embodiments of the guide wire instrument 240 may include a curved section 245 along the distal tip portion 242 so that the electrode assembly follows a curved path as it is advanced into the heart wall tissue 35. As shown in FIG. 9, some embodiments of an electrode delivery system 200 include a curved guide wire instrument 240 that is slidably engageable with a wireless electrode assembly 120. As described in connection with previous embodiments, the wireless electrode assembly 120 may include a guide wire channel 122 that slidably engages the guide wire instrument 240 during advancement into the heart wall tissue 35. Similar to the previously described embodiments, the electrode assembly 120 may be releasably retained in a delivery catheter 130 using a magnetic coupling device 150, and an actuation member 160 may be adjusted in a controlled manner to advance the electrode assembly 120 over the guide wire instrument 240.

Still referring to FIG. 9, when the delivery catheter 130 has been directed to the targeted implantation site along the endocardium 33, the distal tip portion 242 of the guide wire instrument 240 can penetrate through the endocardium 33 and into the heart wall tissue 35. Similar to previous embodiments, the guide wire instrument 240 may include at least one sensor electrode 244 along its distal tip portion 242 that is configured to sense local electrical activity (e.g., an electrogram or the like) and to transmit a test stimulation signal (e.g., a pacing signal) at the implantation site. The distal portion 242 of the guide wire instrument 240 may include at least one curved section 245 that permits the distal portion to penetrate a particular distance before turning and tunneling sideways into the heart wall tissue 35. The radius of curvature, the stiffness of the curved section, and the shape of the remaining portions of the distal tip portion 242 may be selected based at least in part upon the penetration resistance of the myocardium encountered by the distal tip portion 242. In some embodiments, the curved section 245 may be configured to provide the desired penetration depth and curvature into a desired tissue plane between the myocardial tissue fibers. In this embodiment, at least the curved section 245 of the distal tip portion 242 comprises an elastically deformable material such as a shape memory material (e.g., Nitinol or the like) that exhibits elasticity or super elasticity when used in the patient's body. The elastically deformable material the permits the curved section 245 to be substantially straightened while passing through the channel in the actuation member 160 (e.g., passed through the delivery catheter 130 toward the heart chamber wall). Such an elastically deformable material can return to the desired curvature after being released from the restraint in the channel of the actuation member 160.

Referring to FIG. 10, after the guide wire instrument 240 has penetrated in the heart wall tissue 35 and curved in a path non-perpendicular to the endocardial surface 33, the actuation member 160 can be adjusted to advance the electrode assembly 120 over the guide wire 240 and into the tissue 35. As the actuation member 160 applies an insertion force to the electrode assembly 120, the electrode assembly 120 may slidably engage the distal tip portion 242 and penetrate along the curved path toward the direction that is non-perpendicular to the endocardial surface. In some circumstances, the distal section 162 of the actuation member 160 may comprise a flexible material (e.g., a polymer shaft, a shaft comprising metallic coils, or the like) so that it may advance over at least a portion of the curved section 245. As previously described, the actuation member 160 may be controllably adjusted so that the electrode assembly 120 is advanced a selected distance along the guide wire instrument 240. In the embodiment shown in FIG. 10, the electrode assembly 120 includes one or more barbs 129 that extend outward from the body portion 125 when the electrode assembly 120 is deployed into the heart wall tissue 35. The barbs 129 may comprise a shape memory material (e.g., Nitinol or the like) that can flex into a non-deployed configuration (refer to FIG. 9) when the electrode assembly 120 is releasably retained in the delivery catheter 130. The barbs 129 may be deployed as fixation devices to maintain the orientation of the electrode assembly 120 while the actuation member 160 and guide wire instrument 240 are withdrawn from the tissue 35.

Referring to FIGS. 11-13, the distal tip portion 240 of the guide wire instrument 240 may be configured to bend during insertion into the heart wall tissue 35 so as to provide a curved insertion path. For example, as shown in FIG. 11, the distal tip portion 249 may include a pointed tip 249 that penetrates into the tissue 35 before a shape memory curved section (refer to section 245 in FIGS. 9-10) causes the distal tip portion to extend along a curved path in the heart wall tissue 35. In addition or in the alternative, a guide wire instrument 250 may be formed with a flattened tip 259 that can penetrate into the heart wall tissue 35 but subsequently bends when more rigid tissue is encountered. Thus, in some circumstances, the guide wire instrument 250 may be advanced into the heart wall tissue 35 and through the myocardium before encountering a more rigid portion of the epicardial layer. In response thereto, the flattened tip 259 of the guide wire instrument 250 may flex so that the distal portion 252 of the guide wire instrument 250 extends in a curved path through the heart wall tissue 35. In yet another embodiment, a guide wire instrument 260 may include a combination of a pointed and flattened tip 269 that can penetrate into the heart wall tissue 35 but subsequently bends when more rigid tissue is encountered. Such a guide wire instrument 250 or 260 with a bendable tip configuration may be used to form the curved path rather than the previously described shape memory curved section 245.

Referring now to FIGS. 14-15, some embodiments of a guide wire instrument may include a fixation device along the distal tip portion so that the guide wire instrument may be secured to the heart wall tissue 35 during the advancement of the electrode assembly 120 into the tissue 35. Such a fixation device can maintain the position of the guide wire instrument and reduce the likelihood of the distal tip portion being extended or retracted during the electrode assembly insertion process. For example, as shown in FIG. 14, some embodiments of a guide wire instrument 270 may include a fixation device in the form of a helical tine 279 extending from the distal tip portion 272. As such, the guide wire instrument 270 may be twisted as it penetrates into the heart wall tissue 35 so that the distal tip portion 272 is “screwed into” the heart wall tissue 35. After the electrode assembly 120 is advanced into the selected implantation site, the guide wire instrument 270 may be withdrawn by twisting the instrument in the opposite direction to “unscrew from” the heart wall tissue 35. In another example, as shown in FIG. 15, some embodiments of a guide wire instrument 280 may include a fixation device in the form of an adjustable barbs 289 that extend from a non-deployed configuration to a deployed configuration. In these embodiments, the adjustable barbs may be in a non-deployed configuration as the guide wire instrument 280 is passed through the delivery catheter 130 toward the heart wall tissue 35. The adjustable barbs may expand outward (e.g., away from the central guide wire axis) when no longer restrained by the surrounding instruments.

Referring to FIGS. 16-17, some embodiments of an electrode delivery system may include a guide wire instrument having a detachable tip portion. As such, the detachable tip portion may remain engaged with the electrode assembly 120 after it has been embedded in the heart wall tissue 35.

As shown in FIG. 16, one embodiment of an electrode delivery system 300 includes a delivery catheter 130 that can be directed through a guide sheath (not shown in FIG. 16) toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 300 may include a magnetic coupling device 150 to releasably retain the electrode assembly 120 in the delivery catheter 130 and may include an actuation member 160 to advance the electrode assembly 120 over the guide wire instrument 340. The guide wire instrument may be detachable along mating portions 347 and 348 so that the detachable portion 342 remains with the electrode assembly 120 in the heart wall tissue 35.

In operation of the electrode delivery system 300, the delivery catheter 130 may be directed to a targeted site on the endocardium 33, and the guide wire instrument 340 may be inserted through the endocardium 33 and into the heart wall tissue 35. The guide wire instrument 340 may include adjustable barbs 349 extending from a distal tip so as to secure the detachable portion 342 of the guide wire instrument 340 to the heart wall tissue 35. After the guide wire instrument has initiated penetration into the heart wall tissue 35, the actuation member 160 may apply an insertion force to the electrode assembly 120 so that the electrode assembly separates from the magnetic coupling device 150 and advances along the guide wire instrument 340 to a controlled depth. Similar to previously described embodiments, the electrode assembly 120 may include one or more barbs 129 that adjust to a deployed configuration so as to retain the position of the electrode assembly 120 in the heart wall tissue 35. After the electrode assembly 120 is advanced to into the heart wall tissue, the guide wire instrument 340 may be detached along the mating portions 347 and 348 so that the detachable portion 342 remains engaged with the electrode assembly 120, For example, the mating portions 347 and 348 may comprise mating tongue and groove sections that are separable when a torque is applied to the proximal end of the guide wire instrument 340 (similar to the proximal portion 148 shown in FIG. 3). Such a relative twisting action may cause the mating portions 347 and 348 to separate, thereby permitting the guide wire instrument 340 (along with the actuation member 160) to be retracted away from the heart chamber wall. The detachable tip portion 342 of the guide wire instrument 340 may serve as an anchor to the electrode assembly 120 embedded in the heart wall tissue 35. For example, the detachable tip portion 342 may reduce the likelihood of migration and changes in orientation of the electrode assembly 120 after repeated heart contractions.

Referring to FIG. 17, another embodiment of an electrode delivery system 400 includes a guide wire instrument 440 having a detachable tip portion 442 that is curved. In this embodiment, the electrode delivery system 400 includes a delivery catheter 130 that can be directed through a guide sheath (not shown in FIG. 17) toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 400 may include a magnetic coupling device 150 to releasably retain the electrode assembly 120 in the delivery catheter 130 and may include an actuation member 160 to advance the electrode assembly 120 over the guide wire instrument 440. The guide wire instrument 440 may be detachable along mating portions 447 and 448 so that the detachable portion 442 remains with the electrode assembly 120 in the heart wall tissue 35. Also, the guide wire instrument 440 includes two curved sections 445 and 446 so that the guide wire instrument 440 penetrates along a curved path in the heart wall tissue 35.

In operation of the electrode delivery system 400, the delivery catheter 130 may be directed to a targeted site on the endocardium 33, and the guide wire instrument 440 may be inserted through the endocardium 33 and into the heart wall tissue 35. The curved sections 445 and 446 of the guide wire instrument 440 may cause the detachable tip portion 442 to penetrate through the endocardium 33 into the heart wall tissue 35 a certain depth before curving along a path that is non-perpendicular to the endocardial surface 33 and then curve again in a path that returns toward the endocardial surface 33. After the guide wire instrument 440 has initiated penetration into the heart wall tissue 35, the actuation member 160 may apply an insertion force to the electrode assembly 120 so that the electrode assembly 120 separates from the magnetic coupling device 150 and advances along the guide wire instrument 440 for a selected advancement length. Similar to previously described embodiments, the electrode assembly 120 may include one or more barbs 129 that adjust to a deployed configuration so as to retain the position of the electrode assembly 120 in the heart wall tissue 35. After the electrode assembly 120 is advanced to into the heart wall tissue 35, the guide wire instrument 440 may be detached along the mating portions 447 and 448 so that the detachable portion 442 remains engaged with the electrode assembly 120. As such, the guide wire instrument 440 (along with the actuation member 160) can be retracted away from the heart chamber wall. The detachable tip portion 442 of the guide wire instrument 440 may serve as an anchor to the electrode assembly 120 embedded in the heart wall tissue 35. For example, the detachable tip portion 442 can maintain the orientation of the electrode assembly 120 in the heart wall tissue 35 and the second curved sections 446 may inhibit the electrode assembly 120 from forwardly migrating toward the distal tip of the detachable portion 442.

Referring to FIGS. 18-19, some embodiments of an electrode delivery system 500 may include a detachable anchor mechanism 570 that engages the electrode assembly 120 after the guide wire instrument 540 has been withdrawn from the heart wall tissue 35. In this embodiment, the electrode delivery system 500 includes a delivery catheter 130 that can be directed through a guide sheath (not shown in FIGS. 18-19) toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 500 may include a magnetic coupling device 150 to releasably retain the electrode assembly 120 in the delivery catheter 130 and may include an actuation member 160 to advance the electrode assembly 120 over the guide wire instrument 540 that the detachable anchor mechanism 570. The guide wire instrument 540 may be slidably engaged with the detachable anchor mechanism 570, and the wireless electrode assembly may include a guide wire channel 522 so as to slide over the guide wire instrument 540 and the detachable anchor mechanism 570. The anchor mechanism 570 can be detachable along mating portions 577 and 578 so that the detachable distal portion 572 remains with the electrode assembly 120 in the heart wall tissue 35.

In operation of the electrode delivery system 500, the delivery catheter 130 may be directed to a targeted site on the endocardium 33, and the guide wire instrument 540 may be inserted through the endocardium 33 and into the heart wall tissue 35 (refer, for example, to FIG. 18). After the guide wire instrument 540 has penetrated into the heart wall tissue 35, the anchor mechanism 570 may be advanced over the guide wire instrument 540 and into the heart wall tissue 35 to further dilate the opening formed in the endocardium 33 (refer, for example, to FIG. 18). The anchor mechanism 570 may include one or more adjustable barbs 579 extending from a distal tip portion so as to secure the anchor mechanism 570 to the heart wall tissue 35. After the guide wire instrument 540 and the anchor mechanism 570 have initiated penetration into the heart wall tissue 35, the actuation member 160 may apply an insertion force to the electrode assembly 120 so that the electrode assembly 120 separates from the magnetic coupling device 150 and advances over the anchor mechanism 570 for a selected advancement length. When the electrode assembly 120 is advanced to into the heart wall tissue 35, the anchor mechanism 570 may be detached along the mating portions 577 and 578 so that the detachable portion 572 remains engaged with the electrode assembly 120. In these circumstances, the anchor mechanism 570, the guide wire instrument 540, and the actuation member 160 can be retracted away from the heart chamber wall (refer, for example, to FIG. 19). Optionally, the guide wire instrument 540 may be withdrawn from the heart wall tissue before the electrode assembly 120 is advanced over the anchor mechanism 570.

The detachable distal portion 572 of the anchor mechanism 570 may serve as an anchor to the electrode assembly 120 embedded in the heart wall tissue 35. In this embodiment shown in FIG. 19, the mating portion 578 is bent during the detachment process (or elastically biased) so as to engage an inner conical surface 528 of the electrode assembly 120. Such an engagement reduces the likelihood of the electrode assembly 120 migrating proximally away from the adjustable barbs 579 at the distal tip of the detachable portion 572. Accordingly, the detachable distal portion 572 may serve to maintain the orientation of the electrode assembly 120 in the heart wall tissue 35.

Referring now to FIG. 20, some embodiments of an electrode delivery system 600 may include a guide wire instrument 640 having a detachment tip portion 642 configured to engage an inner surface of the electrode assembly 120 when implanted in the heart wall tissue 35. In this embodiment, the electrode delivery system 600 includes a delivery catheter 130 that can be directed through a guide sheath (not shown in FIG. 20) toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 600 may include a magnetic coupling device 150 (not shown in FIG. 20) to releasably retain the electrode assembly 120 in the delivery catheter 130 and may include an actuation member 160 to advance the electrode assembly 120 over the guide wire instrument 640. The guide wire instrument 640 may be detachable along mating portions 647 and 648 so that the detachable portion 642 remains with the electrode assembly 120 in the heart wall tissue 35. Also, the guide wire instrument 640 can include one or more adjustable stoppers 646 to engage one or more inner surfaces of the electrode assembly 120.

In operation of the electrode delivery system 600, the delivery catheter 130 may be directed to a targeted site on the endocardium 33, and the guide wire instrument 640 may be inserted through the endocardium 33 and into the heart wall tissue 35. The guide wire instrument includes one or more adjustable barbs 649 that extend from the distal tip to secure the detachable tip portion 642 to the heart tissue. The adjustable barbs 649 and the adjustable stoppers 646 may be flexed into a non-deployed configuration (e.g., pressed against the guide wire body) when the guide wire instrument is passed through a central channel of the actuation member 160. As the detachable tip portion 642 is inserted into the heart wall tissue, the adjustable barbs 649 and the adjustable stoppers may extend outwardly to a deployed configuration (as shown, for example, in FIG. 20). After the guide wire instrument 640 has initiated penetration into the heart wall tissue 35, the actuation member 160 may apply an insertion force to the electrode assembly 120 so that the electrode assembly 120 separates from the magnetic coupling device 150 and advances along the guide wire instrument 640 for a selected advancement length. The electrode assembly 120 may advance in a distal direction over the stoppers 646 during the insertion process (e.g., the stoppers 646 may partially flex inwardly to permit passage of the electrode assembly 120 in the distal direction). When the electrode assembly is advanced to the selected advancement length, the stoppers 646 may engage one or more inner surfaces 626 of the electrode assembly 120, which can reduce the likelihood of the electrode assembly 120 migrating proximally away from the adjustable barbs 649 at the distal tip of the detachable portion 642.

After the electrode assembly 120 is advanced into the heart wall tissue 35, the guide wire instrument 640 may be detached along the mating portions 647 and 648 so that the detachable portion 642 remains engaged with the electrode assembly 120. As such, the guide wire instrument 640 (along with the actuation member 160) can be retracted away from the heart chamber wall. The detachable tip portion 642 of the guide wire instrument 640 may serve as an anchor to the electrode assembly 120 embedded in the heart wall tissue 35. For instance, the detachable tip portion 642 can maintain the orientation of the electrode assembly 120 in the heart wall tissue 35.

Referring to FIGS. 21-25, some embodiments of an electrode delivery system may include a delivery catheter that is configured to releasably secure to the heart wall tissue 35 during the implantation process. Such a releasable attachment to the heart chamber wall permits the delivery catheter to maintain its position adjacent the targeted implantation site. After the electrode assembly 120 is inserted into the heart wall tissue 35, the delivery catheter may be released from the heart chamber wall and withdrawn into the guide sheath 110.

As shown in FIG. 21, some embodiments of an electrode delivery system 700 may include a delivery catheter 730 having a fixation device to releasably engage the heart wall tissue 35. In this embodiment, the delivery catheter 730 includes a fixation device in the form of a helical tine 735 that extends distally from the tip of the delivery catheter 730. The electrode delivery system 700 includes a guide sheath 110 that slidably receives the delivery catheter 730 so that the delivery catheter can be directed toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 700 may include a magnetic coupling device 150 to releasably retain the electrode assembly 120 (not shown in FIG. 21) in the delivery catheter 730 and may include an actuation member 160 (not shown in FIG. 21) to advance the electrode assembly 120 over the guide wire instrument 140.

In operation, the delivery catheter 730 may be twisted as it approaches the endocardium 33 so that the helical tine 735 is “screwed into” the heart wall tissue 35. After the delivery catheter is secured to the heart wall tissue, the guide wire instrument 140 can penetrate into the heart wall tissue 35 to prepare the insertion path for the electrode assembly 120 (not shown in FIG. 21). When the guide wire instrument has penetrated into the heart wall tissue 35, the electrode assembly 120 may be advanced over the guide wire instrument 140, as described in previous embodiments, for example, in connection with FIGS. 6-8. After insertion of the electrode assembly 120, the guide wire instrument 140 and the actuation member 160 (not shown in FIG. 21) can be retracted into the delivery catheter 730, and the helical tine 735 of the delivery catheter 730 can be “unscrewed” or otherwise released from the heart wall tissue 35. It should be understood that, in some embodiments, the electrode delivery system 700 may include the delivery catheter 730 to releasably secure with the heart wall tissue 35 and may include one or more alternative guide wire instruments, such as those guide wire embodiments previously described in connection with FIGS. 9-17 and 20.

Referring to FIGS. 22-25, some embodiments of an electrode delivery system 800 may include a delivery catheter 830 having at least one adjustable fixation device to releasably engage the heart wall tissue 35. In this embodiment, the delivery catheter 830 includes adjustable fixation devices in the form of adjustable barbs 835 that can be distally extended to curl outwardly from the tip of the delivery catheter 830. The electrode delivery system 800 includes a guide sheath 110 that slidably receives the delivery catheter 830 so that the delivery catheter 830 can be directed toward a targeted site along the endocardium 33. Similar to previously described embodiments, the electrode delivery system 800 may include a magnetic coupling device 150 to releasably retain the electrode assembly 120 (not shown in FIGS. 22-25) in the delivery catheter 830 and may include an actuation member 160 (not shown in FIGS. 22-25) to advance the electrode assembly 120 over the guide wire instrument 140.

In operation, the adjustable barbs 835 may be retracted in a non-deployed configuration as the delivery catheter 830 approaches the endocardium 33 (refer, for example, to FIGS. 23-24). The adjustable barbs 835 may be coupled with a slider ring 836 that is extended and retracted by a threaded ring 837. The threaded ring 837 may be engaged by mating threads 838 along an inner distal surface of the delivery catheter 830. As such, an actuation shaft 839 that is fixedly attached to the threaded ring 837 may be twisted so as to turn the threaded ring 837 relative to the threads 838. Such a turning motion causes the threaded ring 837 to push (or pull) the slider ring 836 between the non-deployed configuration (FIG. 24) and the deployed configuration (FIG. 25). As the slider ring 836 is moved to the distal position (FIG. 25), the adjustable barbs 835 may extend distally from the delivery catheter 830 to engage the heart wall tissue 35. In this embodiment, the adjustable barbs 835 may comprise a shape memory material (e.g., Nitinol or the like) so that the barbs 835 curl outwardly away from the distal tip of the delivery catheter 830 when disposed in the deployed configuration. Such an embodiment permits the barbs to be flexed into a generally non-curved, longitudinal orientation when disposed in the non-deployed configuration (as shown, for example, in FIG. 24).

After the delivery catheter 830 is secured to the heart wall tissue 35, the guide wire instrument 140 can penetrate into the heart wall tissue 35, as shown in FIG. 22, to prepare the insertion path for the electrode assembly 120 (the electrode assembly 120 is not shown in FIG. 22). When the guide wire instrument has penetrated into the heart wall tissue 35, the electrode assembly 120 may be advanced over the guide wire instrument 140, as described in previous embodiments, for example, in connection with FIGS. 6-8. After insertion of the electrode assembly 120, the guide wire instrument 140 and the actuation member 160 (not shown in FIGS. 22-25) can be retracted into the delivery catheter 830, and the adjustable barbs 835 of the delivery catheter 830 can be released from the heart wall tissue 35. It should be understood that, in some embodiments, the electrode delivery system 800 may include the delivery catheter 830 to releasably secure with the heart wall tissue 35 and may include one or more alternative guide wire instruments, such as those guide wire embodiments previously described in connection with FIGS. 9-17 and 20.

Accordingly, in these embodiments, the delivery catheter 730 or 830 may be configured to releasably secured to the heart wall tissue 35 during the implantation process. Such a releasable attachment to the heart chamber wall permits the delivery catheter 730 or 830 to maintain its position adjacent the targeted implantation site. After the electrode assembly 120 is inserted into the heart wall tissue 35, the delivery catheter 730 or 830 may be released from the heart chamber wall and withdrawn into the guide sheath.

It should be understood from the description here that the delivery system 100 can be employed to deliver electrode assemblies 120 to locations in the body other than the human 30. For example, the guide sheath 110 and delivery catheter 130 can be used to implant one or electrode assemblies 120 to tissue in the digestive tract (e.g., stomach tissue) for electrical stimulation treatment of digestive conditions or obesity. In another example, the guide sheath 110 and delivery catheter 130 can be used to implant one or electrode assemblies 120 to tissue in the urinary tract (e.g., urinary sphincter) for electrical stimulation treatment of incontinence or other urinary conditions.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

Claims

1. A method of implanting a leadless cardiac pacing device in a patient, the method comprising: inserting a distal end of a guide wire into a vessel of a cardiovascular system of the patient;advancing a leadless cardiac pacing device along the guide wire through the vessel to a cardiovascular implantation site in the cardiovascular system, the leadless cardiac pacing device including a battery and a plurality of electrodes for providing electrical stimulation to cardiac tissue; andthereafter, withdrawing the guide wire from the cardiovascular system.
2. The method of claim 1, further comprising, inserting a guide sheath in the vessel; andwherein the step of advancing the leadless cardiac pacing device along the guide wire includes advancing the leadless cardiac pacing device through the guide sheath.
3. The method of claim 2, wherein the guide sheath includes a steering mechanism to deflect a distal end of the guide sheath.
4. The method of claim 2, wherein the step of advancing the leadless cardiac pacing device along the guide wire includes advancing a delivery catheter through the guide sheath with the leadless cardiac pacing device detachably coupled to the delivery catheter.
5. The method of claim 4, further comprising, advancing the leadless cardiac pacing device out of a distal opening of the guide sheath at the cardiovascular implantation site.
6. The method of claim 5, further comprising, engaging the leadless cardiac pacing device with a heart chamber wall at the cardiovascular implantation site.
7. The method of claim 1, wherein the step of advancing the leadless cardiac pacing device along the guide wire includes advancing a delivery catheter through the vessel of the cardiovascular system with the leadless cardiac pacing device detachably coupled to the delivery catheter.
8. The method of claim 7, further comprising: decoupling the leadless cardiac pacing device from the delivery catheter, andthereafter, withdrawing the delivery catheter from the cardiovascular system.
9. The method of claim 7, wherein the delivery catheter includes a steering mechanism to deflect a distal end of the delivery catheter.
10. The method of claim 1, wherein the cardiovascular implantation site is in a heart of the cardiovascular system.
11. A method of implanting a leadless cardiac pacing device in a patient, the method comprising: positioning a guide sheath into a vessel of a cardiovascular system of the patient;positioning a guide wire through a lumen of the guide sheath with a distal end of the guide wire extending distally beyond a distal end of the guide sheath;advancing a leadless cardiac pacing device along the guide wire within the lumen of the guide sheath to deploy the leadless cardiac pacing device at a cardiovascular implantation site in the cardiovascular system distal of the distal end of the guide sheath, the leadless cardiac pacing device including a battery and a plurality of electrodes for providing electrical stimulation to cardiac tissue; andthereafter, withdrawing the guide wire and the guide sheath from the cardiovascular system.
12. The method of claim 11, wherein the guide sheath includes a steering mechanism to deflect the distal end of the guide sheath.
13. The method of claim 2, wherein the step of advancing the leadless cardiac pacing device along the guide wire includes advancing a delivery catheter through the guide sheath with the leadless cardiac pacing device detachably coupled to the delivery catheter.
14. The method of claim 13, wherein the cardiovascular implantation site is in a heart of the cardiovascular system.
15. The method of claim 14, further comprising, engaging the leadless cardiac pacing device with a heart chamber wall at the cardiovascular implantation site.
16. The method of claim 13, wherein the delivery catheter includes a steering mechanism to deflect a distal end of the steering catheter.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 15/495,612, filed Apr. 24, 2017, which is a Continuation of U.S. application Ser. No. 15/058,941, filed Mar. 2, 2016, now issued as U.S. Pat. No. 9,662,487, which is a Continuation of U.S. application Ser. No. 13/476,599, filed May 21, 2012, now issued as U.S. Pat. No. 9,308,374, which is a Continuation of U.S. application Ser. No. 12/910,106, filed on Oct. 22, 2010, now issued as U.S. Pat. No. 8,185,213, which is a Division of U.S. application Ser. No. 11/490,916, filed Jul. 21, 2006, now issued as U.S. Pat. No. 7,840,281, the benefit of priority of each of which are claimed herein, and each of which are hereby incorporated herein by reference in its respective entirety.

US Referenced Citations (374)

Number	Name	Date	Kind
3057356	Greatbatch	Oct 1962	A
3357434	Abell	Dec 1967	A
3596662	Bolduc	Aug 1971	A
3667477	Susset et al.	Jun 1972	A
3713449	Mulier	Jan 1973	A
3727616	Lenzkes	Apr 1973	A
3835864	Rasor et al.	Sep 1974	A
3902501	Citron et al.	Sep 1975	A
3942535	Schulman	Mar 1976	A
3943936	Rasor et al.	Mar 1976	A
4010756	DuMont et al.	Mar 1977	A
4157720	Greatbatch	Jun 1979	A
4162679	Reenstierna	Jul 1979	A
4198991	Harris	Apr 1980	A
4256115	Bilitch	Mar 1981	A
4441210	Hochmair et al.	Apr 1984	A
4525774	Kino et al.	Jun 1985	A
4543955	Schroeppel	Oct 1985	A
4641664	Botvidsson	Feb 1987	A
4644957	Ricciardelli et al.	Feb 1987	A
4681111	Silvian	Jul 1987	A
4721118	Harris	Jan 1988	A
4815469	Cohen	Mar 1989	A
4830006	Haluska et al.	May 1989	A
4858623	Bradshaw et al.	Aug 1989	A
4860750	Frey et al.	Aug 1989	A
4913164	Greene et al.	Apr 1990	A
4953564	Berthelsen	Sep 1990	A
4987897	Funke	Jan 1991	A
4991578	Cohen	Feb 1991	A
5012806	De Bellis	May 1991	A
5078736	Behl	Jan 1992	A
5113869	Nappholz et al.	May 1992	A
5139033	Everett et al.	Aug 1992	A
5143090	Dutcher et al.	Sep 1992	A
5170802	Mehra	Dec 1992	A
5178149	Imburgia et al.	Jan 1993	A
5193539	Schulman et al.	Mar 1993	A
5193540	Schulman et al.	Mar 1993	A
5234437	Sepetka	Aug 1993	A
5243977	Trabucco et al.	Sep 1993	A
5246014	Williams et al.	Sep 1993	A
5250071	Palermo	Oct 1993	A
5255693	Dutcher et al.	Oct 1993	A
5261916	Engelson	Nov 1993	A
5300107	Stokes et al.	Apr 1994	A
5304195	Twyford, Jr. et al.	Apr 1994	A
5312415	Palermo	May 1994	A
5312439	Loeb	May 1994	A
5314458	Najafi et al.	May 1994	A
5324316	Schulman et al.	Jun 1994	A
5324325	Moaddeb	Jun 1994	A
5335664	Nagashima	Aug 1994	A
5336252	Cohen	Aug 1994	A
5342408	deCoriolis et al.	Aug 1994	A
5350397	Palermo et al.	Sep 1994	A
5383915	Adams	Jan 1995	A
5383924	Brehier	Jan 1995	A
5405367	Schulman et al.	Apr 1995	A
5411535	Fujii et al.	May 1995	A
5411537	Munshi et al.	May 1995	A
5447533	Vachon et al.	Sep 1995	A
5487760	Villafana	Jan 1996	A
5531780	Vachon	Jul 1996	A
5571148	Loeb et al.	Nov 1996	A
5591217	Barreras	Jan 1997	A
5622168	Keusch et al.	Apr 1997	A
5624316	Roskowski et al.	Apr 1997	A
5628778	Kruse et al.	May 1997	A
5674259	Gray	Oct 1997	A
5735887	Barreras, Sr. et al.	Apr 1998	A
5755764	Schroeppel	May 1998	A
5769877	Barreras, Sr.	Jun 1998	A
5772693	Brownlee	Jun 1998	A
5775331	Raymond et al.	Jul 1998	A
5779715	Tu	Jul 1998	A
5792208	Gray	Aug 1998	A
5800535	Howard, III	Sep 1998	A
5807397	Barreras	Sep 1998	A
5814089	Stokes et al.	Sep 1998	A
5833715	Vachon et al.	Nov 1998	A
5851227	Spehr	Dec 1998	A
5861019	Sun et al.	Jan 1999	A
5871532	Schroeppel	Feb 1999	A
5876429	Schroeppel	Mar 1999	A
5876431	Spehr et al.	Mar 1999	A
5954757	Gray	Sep 1999	A
5995876	Kruse et al.	Nov 1999	A
6006139	Kruse et al.	Dec 1999	A
6035239	Patag et al.	Mar 2000	A
6041258	Cigaina et al.	Mar 2000	A
6044300	Gray	Mar 2000	A
6053873	Govari et al.	Apr 2000	A
6115636	Ryan	Sep 2000	A
6123724	Denker	Sep 2000	A
6132456	Sommer et al.	Oct 2000	A
6141588	Cox et al.	Oct 2000	A
6141591	Lenarz et al.	Oct 2000	A
6144879	Gray	Nov 2000	A
6144880	Ding et al.	Nov 2000	A
6161029	Spreigl et al.	Dec 2000	A
6164284	Schulman et al.	Dec 2000	A
6200303	Verrior et al.	Mar 2001	B1
6208894	Schulman et al.	Mar 2001	B1
6223079	Bakels et al.	Apr 2001	B1
6240316	Richmond et al.	May 2001	B1
6266567	Ishikawa et al.	Jul 2001	B1
6315721	Schulman et al.	Nov 2001	B2
6317615	KenKnight et al.	Nov 2001	B1
6322559	Daulton et al.	Nov 2001	B1
6336937	Vonesh et al.	Jan 2002	B1
6345202	Richmond et al.	Feb 2002	B2
6351673	Ding et al.	Feb 2002	B1
6360127	Ding et al.	Mar 2002	B1
6363279	Ben-Haim et al.	Mar 2002	B1
6363938	Saadat et al.	Apr 2002	B2
6370434	Zhang et al.	Apr 2002	B1
6381495	Jenkins	Apr 2002	B1
6385472	Hall et al.	May 2002	B1
6409674	Brockway et al.	Jun 2002	B1
6441747	Khair et al.	Aug 2002	B1
6442413	Silver	Aug 2002	B1
6445953	Bulkes et al.	Sep 2002	B1
6456256	Amundson et al.	Sep 2002	B1
6501983	Natarajan et al.	Dec 2002	B1
6510345	Van Bentem	Jan 2003	B1
6522926	Kieval et al.	Feb 2003	B1
6542775	Ding et al.	Apr 2003	B2
6556874	Audoglio	Apr 2003	B2
6564807	Schulman et al.	May 2003	B1
6571127	Ben-Haim et al.	May 2003	B1
6574510	Von Arx et al.	Jun 2003	B2
6582441	He et al.	Jun 2003	B1
6589230	Gia et al.	Jul 2003	B2
6614406	Amundson et al.	Sep 2003	B2
6647291	Bonner et al.	Nov 2003	B1
6647292	Bardy et al.	Nov 2003	B1
6783499	Schwartz	Aug 2004	B2
6856836	Ding et al.	Feb 2005	B2
6859665	Ding et al.	Feb 2005	B2
6895265	Silver	May 2005	B2
6895280	Meadows et al.	May 2005	B2
6897788	Khair et al.	May 2005	B2
6901294	Whitehurst et al.	May 2005	B1
6907285	Denker et al.	Jun 2005	B2
6917833	Denker et al.	Jul 2005	B2
6947792	Ben-Haim et al.	Sep 2005	B2
6970742	Mann et al.	Nov 2005	B2
6978173	Stoll et al.	Dec 2005	B2
7003350	Denker et al.	Feb 2006	B2
7006864	Echt et al.	Feb 2006	B2
7050849	Echt et al.	May 2006	B2
7054691	Kuzma et al.	May 2006	B1
7062318	Ben-Haim et al.	Jun 2006	B2
7076305	Imran et al.	Jul 2006	B2
7184830	Echt et al.	Feb 2007	B2
7200437	Nabutovsky et al.	Apr 2007	B1
7209783	Fellows et al.	Apr 2007	B2
7231260	Wallace et al.	Jun 2007	B2
7289853	Campbell et al.	Oct 2007	B1
7410497	Hastings et al.	Aug 2008	B2
7522962	Doron et al.	Apr 2009	B1
7532932	Denker et al.	May 2009	B2
7532933	Hastings et al.	May 2009	B2
7558631	Cowan et al.	Jul 2009	B2
7565195	Kroll et al.	Jul 2009	B1
7606621	Brisken et al.	Oct 2009	B2
7610092	Cowan et al.	Oct 2009	B2
7615010	Najafi et al.	Nov 2009	B1
7634313	Kroll et al.	Dec 2009	B1
7647109	Hastings et al.	Jan 2010	B2
7650186	Hastings et al.	Jan 2010	B2
7702392	Echt et al.	Apr 2010	B2
7765001	Echt et al.	Jul 2010	B2
7809438	Echt et al.	Oct 2010	B2
7840281	Kveen et al.	Nov 2010	B2
7848815	Brisken et al.	Dec 2010	B2
7848823	Drasler et al.	Dec 2010	B2
7877136	Moffitt et al.	Jan 2011	B1
7877142	Moaddeb et al.	Jan 2011	B2
7890173	Brisken et al.	Feb 2011	B2
7894904	Cowan et al.	Feb 2011	B2
7894907	Cowan et al.	Feb 2011	B2
7894910	Cowan et al.	Feb 2011	B2
7899537	Kroll et al.	Mar 2011	B1
7899541	Cowan et al.	Mar 2011	B2
7899542	Cowan et al.	Mar 2011	B2
7904170	Harding	Mar 2011	B2
7937148	Jacobson	May 2011	B2
7937161	Hastings et al.	May 2011	B2
7945333	Jacobson	May 2011	B2
7996087	Cowan et al.	Aug 2011	B2
8010209	Jacobson	Aug 2011	B2
8019419	Panescu et al.	Sep 2011	B1
8032219	Neumann et al.	Oct 2011	B2
8050774	Kveen et al.	Nov 2011	B2
8165694	Carbanaru et al.	Apr 2012	B2
8185213	Kveen et al.	May 2012	B2
8204595	Pianca et al.	Jun 2012	B2
8204605	Hastings et al.	Jun 2012	B2
8260416	Ben-Haim et al.	Sep 2012	B2
8290600	Hastings et al.	Oct 2012	B2
8332036	Hastings et al.	Dec 2012	B2
8340780	Hastings et al.	Dec 2012	B2
8352025	Jacobson	Jan 2013	B2
8478408	Hastings et al.	Jul 2013	B2
8644934	Hastings et al.	Feb 2014	B2
20010018547	Mechlenburg	Aug 2001	A1
20020026228	Schauerte	Feb 2002	A1
20020052632	Ben-Haim et al.	May 2002	A1
20020065543	Gomperz et al.	May 2002	A1
20020077556	Schwartz	Jun 2002	A1
20020077685	Sundquist et al.	Jun 2002	A1
20020123774	Loeb et al.	Sep 2002	A1
20020123785	Zhang et al.	Sep 2002	A1
20020128546	Silver	Sep 2002	A1
20020138009	Brockway et al.	Sep 2002	A1
20020138100	Stoll et al.	Sep 2002	A1
20020183791	Denker et al.	Dec 2002	A1
20020188323	Penner et al.	Dec 2002	A1
20020198604	Schulman et al.	Dec 2002	A1
20030036773	Whitehurst et al.	Feb 2003	A1
20030050681	Pianca et al.	Mar 2003	A1
20030055465	Ben-Haim et al.	Mar 2003	A1
20030055466	Ben-Haim et al.	Mar 2003	A1
20030055467	Ben-Haim et al.	Mar 2003	A1
20030074041	Parry et al.	Apr 2003	A1
20030088278	Bardy et al.	May 2003	A1
20030109914	Westlund et al.	Jun 2003	A1
20030114735	Silver et al.	Jun 2003	A1
20030114742	Lewkowicz et al.	Jun 2003	A1
20030158584	Cates et al.	Aug 2003	A1
20030172388	Fujise et al.	Sep 2003	A1
20030181958	Dobak, III	Sep 2003	A1
20030181959	Dobak, III	Sep 2003	A1
20030204206	Padua et al.	Oct 2003	A1
20030216729	Marchitto et al.	Nov 2003	A1
20030236518	Marchitto et al.	Dec 2003	A1
20040019364	Kieval et al.	Jan 2004	A1
20040059280	Makower et al.	Mar 2004	A1
20040059392	Parramon et al.	Mar 2004	A1
20040073267	Holzer	Apr 2004	A1
20040087831	Michels et al.	May 2004	A1
20040097805	Verard et al.	May 2004	A1
20040098068	Carbunaru et al.	May 2004	A1
20040102830	Williams	May 2004	A1
20040103906	Schulman et al.	Jun 2004	A1
20040106954	Whitehurst et al.	Jun 2004	A1
20040127895	Flock et al.	Jul 2004	A1
20040147969	Mann et al.	Jul 2004	A1
20040147973	Hauser	Jul 2004	A1
20040167580	Mann et al.	Aug 2004	A1
20040171355	Yu et al.	Sep 2004	A1
20040172083	Penner	Sep 2004	A1
20040176672	Silver et al.	Sep 2004	A1
20040176822	Thompson et al.	Sep 2004	A1
20040193092	Deal	Sep 2004	A1
20040193229	Starkebaum et al.	Sep 2004	A1
20040210282	Flock et al.	Oct 2004	A1
20040215092	Fischell et al.	Oct 2004	A1
20040215280	Dublin et al.	Oct 2004	A1
20040230090	Hegde et al.	Nov 2004	A1
20040230255	Dobak, III	Nov 2004	A1
20050021108	Klosterman et al.	Jan 2005	A1
20050025797	Wang et al.	Feb 2005	A1
20050043765	Williams et al.	Feb 2005	A1
20050051243	Forbes Jones et al.	Mar 2005	A1
20050057905	He et al.	Mar 2005	A1
20050065575	Dobak	Mar 2005	A1
20050080346	Gianchandani et al.	Apr 2005	A1
20050080459	Jacobson et al.	Apr 2005	A1
20050095197	Tuszynski et al.	May 2005	A1
20050096702	Denker et al.	May 2005	A1
20050131511	Westlund	Jun 2005	A1
20050136385	Mann et al.	Jun 2005	A1
20050149138	Min et al.	Jul 2005	A1
20050165456	Mann et al.	Jul 2005	A1
20050182456	Ziobro et al.	Aug 2005	A1
20050182465	Ness	Aug 2005	A1
20050192637	Girouard et al.	Sep 2005	A1
20050215764	Tuszynski et al.	Sep 2005	A1
20050245846	Casey	Nov 2005	A1
20050249667	Tuszynski et al.	Nov 2005	A1
20050251238	Wallace et al.	Nov 2005	A1
20050251240	Doan	Nov 2005	A1
20050256549	Holzer	Nov 2005	A1
20050261741	Libbus et al.	Nov 2005	A1
20050273014	Gianchandani et al.	Dec 2005	A1
20050288596	Eigler et al.	Dec 2005	A1
20050288717	Sunagawa	Dec 2005	A1
20050288727	Penner	Dec 2005	A1
20060015097	Mulier et al.	Jan 2006	A1
20060020316	Martinez et al.	Jan 2006	A1
20060064135	Brockway	Mar 2006	A1
20060085039	Hastings et al.	Apr 2006	A1
20060085041	Hastings et al.	Apr 2006	A1
20060085042	Hastings et al.	Apr 2006	A1
20060095089	Soykan et al.	May 2006	A1
20060136001	Ortega et al.	Jun 2006	A1
20060136004	Cowan et al.	Jun 2006	A1
20060173504	Zhu et al.	Aug 2006	A1
20060173505	Salo et al.	Aug 2006	A1
20060178719	Ideker et al.	Aug 2006	A1
20060206170	Denker et al.	Sep 2006	A1
20060241705	Neumann et al.	Oct 2006	A1
20070075905	Denker et al.	Apr 2007	A1
20070078490	Cowan et al.	Apr 2007	A1
20070088394	Jacobson	Apr 2007	A1
20070088396	Jacobson	Apr 2007	A1
20070088397	Jacobson	Apr 2007	A1
20070088398	Jacobson	Apr 2007	A1
20070088418	Jacobson	Apr 2007	A1
20070106357	Denker et al.	May 2007	A1
20070135882	Drasler et al.	Jun 2007	A1
20070135883	Drasler et al.	Jun 2007	A1
20070150009	Kveen et al.	Jun 2007	A1
20070150037	Hastings et al.	Jun 2007	A1
20070150038	Hastings et al.	Jun 2007	A1
20070162079	Shemer et al.	Jul 2007	A1
20070203556	Rutten et al.	Aug 2007	A1
20070219590	Hastings et al.	Sep 2007	A1
20070239248	Hastings et al.	Oct 2007	A1
20070276444	Gelbart et al.	Nov 2007	A1
20070293904	Gelbart et al.	Dec 2007	A1
20080021505	Hastings et al.	Jan 2008	A1
20080021532	Kveen et al.	Jan 2008	A1
20080039904	Bulkes et al.	Feb 2008	A1
20080046040	Denker et al.	Feb 2008	A1
20080077184	Denker et al.	Mar 2008	A1
20080077188	Denker et al.	Mar 2008	A1
20080109054	Hastings et al.	May 2008	A1
20080119911	Rosero	May 2008	A1
20080140142	Darvish et al.	Jun 2008	A1
20080262588	Zarembo et al.	Oct 2008	A1
20080288039	Reddy	Nov 2008	A1
20080306359	Zdeblick et al.	Dec 2008	A1
20080319502	Sunagawa et al.	Dec 2008	A1
20090018599	Hastings et al.	Jan 2009	A1
20090082827	Kveen et al.	Mar 2009	A1
20090082828	Ostroff	Mar 2009	A1
20090088813	Brockway et al.	Apr 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090234407	Hastings et al.	Sep 2009	A1
20090275998	Burnes et al.	Nov 2009	A1
20100094367	Sen	Apr 2010	A1
20100100144	Shuros et al.	Apr 2010	A1
20100198288	Ostroff	Aug 2010	A1
20100228308	Cowan et al.	Sep 2010	A1
20100286744	Echt et al.	Nov 2010	A1
20100314775	Schwarzbauer	Dec 2010	A1
20110034939	Kveen et al.	Feb 2011	A1
20110071586	Jacobson	Mar 2011	A1
20110077708	Ostroff	Mar 2011	A1
20110190835	Brockway et al.	Aug 2011	A1
20110208260	Jacobson	Aug 2011	A1
20110213233	Stevenson et al.	Sep 2011	A1
20110218587	Jacobson	Sep 2011	A1
20110237967	Moore et al.	Sep 2011	A1
20110251660	Griswold	Oct 2011	A1
20110251662	Griswold et al.	Oct 2011	A1
20110270339	Murray, III et al.	Nov 2011	A1
20110270340	Pellegrini et al.	Nov 2011	A1
20110282423	Jacobson	Nov 2011	A1
20120078322	Dal Molin et al.	Mar 2012	A1
20120089198	Ostroff	Apr 2012	A1
20120095521	Hintz	Apr 2012	A1
20120095539	Khairkhahan et al.	Apr 2012	A1
20120101540	O'Brien et al.	Apr 2012	A1
20120109236	Jacobson et al.	May 2012	A1
20120109259	Bond et al.	May 2012	A1
20120116489	Khairkhahan et al.	May 2012	A1
20120158111	Khairkhahan et al.	Jun 2012	A1
20120172690	Anderson et al.	Jul 2012	A1
20130268042	Hastings et al.	Oct 2013	A1

Foreign Referenced Citations (76)

Number	Date	Country
0758542	Feb 1997	EP
0904009	Mar 1999	EP
1166820	Jan 2002	EP
1166832	Jan 2002	EP
1264572	Dec 2002	EP
0904009	Sep 2003	EP
1809372	Jul 2007	EP
1812104	Aug 2007	EP
1835962	Sep 2007	EP
2559391	Aug 1985	FR
61203730	Sep 1986	JP
62254770	Nov 1987	JP
02307481	Dec 1990	JP
05076501	Mar 1993	JP
05245215	Sep 1993	JP
6510459	Nov 1994	JP
7016299	Jan 1995	JP
9508054	Aug 1997	JP
2000502931	Mar 2000	JP
2001511406	Aug 2001	JP
2002510222	Apr 2002	JP
2002514478	May 2002	JP
2004173790	Jun 2004	JP
2005245215	Sep 2005	JP
2010509901	Mar 2010	JP
526115	Oct 2006	NZ
539770	Oct 2007	NZ
539771	Oct 2007	NZ
9116864	Nov 1991	WO
9308871	May 1993	WO
9510226	Apr 1995	WO
9620754	Jul 1996	WO
9639932	Dec 1996	WO
9725098	Jul 1997	WO
9745157	Dec 1997	WO
9826840	Jun 1998	WO
9829030	Jul 1998	WO
9857592	Dec 1998	WO
9903533	Jan 1999	WO
9906102	Feb 1999	WO
9958191	Nov 1999	WO
9964104	Dec 1999	WO
0030534	Jun 2000	WO
0100114	Jan 2001	WO
0187137	Nov 2001	WO
03041793	May 2003	WO
03053491	Jul 2003	WO
03076010	Sep 2003	WO
03082403	Oct 2003	WO
03096918	Nov 2003	WO
03099102	Dec 2003	WO
2004002572	Jan 2004	WO
2004012811	Feb 2004	WO
2004032788	Apr 2004	WO
2004078025	Sep 2004	WO
2005058143	Jun 2005	WO
2005096954	Oct 2005	WO
2005101660	Oct 2005	WO
2005107852	Nov 2005	WO
2005107863	Nov 2005	WO
2005117737	Dec 2005	WO
2006045073	Apr 2006	WO
2006045074	Apr 2006	WO
2006045075	Apr 2006	WO
2006096685	Sep 2006	WO
2007067231	Jun 2007	WO
2007067253	Jun 2007	WO
2007078770	Jul 2007	WO
2007115044	Oct 2007	WO
2008011626	Jan 2008	WO
2007115044	Feb 2008	WO
2008034005	Mar 2008	WO
2008111998	Sep 2008	WO
2009099550	Aug 2009	WO
2009099597	Aug 2009	WO
2012082755	Jun 2012	WO

Non-Patent Literature Citations (244)

Entry
“International Application Serial No. PCT/US2005/037979, International Search Report dated Mar. 21, 2006” 4 pgs.
“International Application Serial No. PCT/US2005/037979, Written Opinion dated Mar. 21, 2006”, 8 pgs.
“International Application Serial No. PCT/US2006/040291, Search Report dated Apr. 4, 2006”, 5 pgs.
“International Application Serial No. PCT/US2006/040291, Written Opinion dated Apr. 4, 2007”, 9 pgs.
“International Application Serial No. PCT/US2007/074315, International Search Report dated Nov. 6, 2007” 4 pgs.
“International Application Serial No. PCT/US2007/074315, Written Opinion dated Nov. 6, 2007” 8 pgs.
“International Application Serial No. PCT/US2007/078405, International Search Report dated May 20, 2008”, p. 220, 7 pgs.
“International Application Serial No. PCT/US2007/078405,Written Opinion dated May 20, 2008”, p. 237, 7 pgs.
“International Application Serial No. PCT/US2009/000587, International Search Report dated Apr. 24, 2009”, 7 pgs.
“International Application Serial No. PCT/US2009/000587, Written Opinion dated Apr. 24, 2009”, 8 pgs.
“International Application Serial No. PCT/US2009/000693, International Search Report dated May 8, 2009”, 5 pgs.
“International Application Serial No. PCT/US2009/000693, Written Opinion dated May 8, 2009”, 8 pgs.
“Japanese Application Serial No. 2007-538087, Office Action dated Apr. 11, 2011”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2007-538087, Office Action dated Oct. 5, 2011”, (W/ English Translation), 14 pgs.
“Japanese Application Serial No. 2007-538087, Response filed Jun. 27, 2011 to Office Action dated Apr. 11, 2011”, (W/ English Translation of Amended Claims), 12 pgs.
“Japanese Application Serial No. 2007-538088, Notice of Final Rejection dated Dec. 6, 2011”, (W/ English Translation), 9 pgs.
“Japanese Application Serial No. 2007-538088, Office Action dated Jun. 13, 2011”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2007-538088, Response filed Aug. 25, 2011 to Office Action dated Jun. 13, 2011” (W/ English Translation of Amended Claims), 9 pgs.
“Japanese Application Serial No. 2007-538089, Office Action dated Mar. 3, 2011”, (W/ English Translation), 6 pgs.
“Japanese Application Serial No. 2007-538089, Response filed May 25, 2011 to Office Action dated Mar. 3, 2011”, (W/ English Translation of Amended Claims), 8 pgs.
“Japanese Application Serial No. 2008-544324, Office Action dated Nov. 22, 2011”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2008544332, Office Action dated Nov. 29, 2011”, (W/ English Translation), 5 pgs.
“Telemetry Research Transcutaneous Energy Transfer (TET) Technology Summary”, Telemetry Research Ltd., www.telemetryresearch.com, (No date listed), 1 pg.
Busch, M., et al., “On the Heating of Inductively Coupled Resonators (Stents) During MRI Examination”, Magnetic Resonance in Medicine, 54, (2005), 775-785.
Manoharan, G., et al., “Novel Passive Implantable atrial defibrillator using transcutaneous radiofrequency energy transmission successfully cardioverts atrial fibrillation”, Circulation, 108(11), (Sep. 16, 2003), 1382-8.
Piella, J. P., “Energy management, wireless and system solutions for highly integrated implantable devices”, Doctoral Thesis by Jordi Parramon I Piella for the Universitat Autonoma de Barcelona, certified Dec. 2001, 62 pgs.
Si, Ping, et al., “A Frequency Control Method for Regulating Wireless Power to Implantable Devices”, IEEE Transactions on Biomedical Circuits and Systems, 2(1), (Mar. 2008), 22-29.
Swain, E., “Breakthrough Products Could put Lesser-Known Firms on the map”, MDDI, (Apr. 2004), 6 pgs.
Wagner, Brian K. “Electrodes, Leads, and Biocompatibility”, Chapter 6—Design of Cardiac Pacemakers, edited by John G. Webster., (1995), 133-160.
“U.S. Appl. No. 11/394,601, Response filed May 4, 2009 to Restriction Requirement dated Apr. 2, 2009”, 9 pgs.
“U.S. Appl. No. 11/490,576, Notice of Allowance dated Jun. 4, 2012”, 8 pgs.
“U.S. Appl. No. 11/490,576, Response filed Apr. 9, 2012 to Non Final Office Action dated No. 9, 2011”, 11 pgs.
“U.S. Appl. No. 11/683,584, Notice of Allowance dated Aug. 7, 2012”, 6 pgs.
“U.S. Appl. No. 11/745,105, Non Final Office Action dated Feb. 7, 2012”, 12 pgs.
“U.S. Appl. No. 11/745,105, Notice of Allowance dated Aug. 20, 2012”, 5 pgs.
“U.S. Appl. No. 11/745,105, Response filed Aug. 6, 2012 to Non Final Office Action dated Feb. 7, 2012”, 11 pgs.
“U.S. Appl. No. 12/361,884, Advisory Action dated Sep. 10, 2012”, 3 pgs.
“U.S. Appl. No. 12/361,884, Examiners Interview Summary dated Oct. 1, 2012”, 3 pgs.
“U.S. Appl. No. 12/361,884, Final Office Action dated Jul. 3, 2012”, 17 pgs.
“U.S. Appl. No. 12/361,884, Response filed Apr. 12, 2012 to Non Final Office Action dated Oct. 12, 2011”, 21 pgs.
“U.S. Appl. No. 12/361,884, Response filed Aug. 28, 2012 to Final Office Action dated Jul. 3, 2012”, 18 pgs.
“U.S. Appl. No. 12/361,884, Response filed Oct. 3, 2012 to Final Office Action dated Jul. 3, 2012”, 18 pgs.
“U.S. Appl. No. 12/365,428, Notice of Allowance dated Feb. 22, 2012”, 7 pgs.
“U.S. Appl. No. 12/365,428, Response filed Jan. 31, 2012 to Non Final Office Action dated Aug. 31, 2011”, 15 pgs.
“U.S. Appl. No. 11/549,352, Appeal Decision mailed Jul. 17, 2012”, 9 pgs.
“European Application Serial No. 05815206.7, Office Action dated May 16, 2012”. 4 pgs.
“European Application Serial No. 05815206.7, Office Action dated Sep. 12, 2012”, 27 pgs.
“European Application Serial No. 05817448.3, Office Action dated May 16, 2012”, 5 pgs.
“European Application Serial No. 05817448.3, Response filed Sep. 14, 2012 to Office Action dated May 16, 2012”, 14 pgs.
“European Application Serial No. 06790023.3, Office Action dated Jul. 16, 2008”, 2 pgs.
“European Application Serial No. 06790023.3, Response filed Aug. 20, 2008 to Office Action dated Jul. 16, 2008”, 17 pgs.
“European Application Serial No. 06790023.3, Response filed Sep. 14, 2009 to Office Action dated Mar. 4, 2009”, 11 pgs.
“European Application Serial No. 06825988.6, Office Action dated Jul. 16, 2008”, 2 pgs.
“European Application Serial No. 06825988.6, Response filed Aug. 20, 2008 to Office Action dated Jul. 16, 2008”, 26 pgs.
“European Application Serial No. 06825988.6, Response filed Sep. 14, 2009 to Office Action dated Mar. 4, 2009”, 12 pgs.
“International Application Serial No. PCT/US2005/037977, International Preliminary Report on Patentability dated Apr. 24, 2007”, 9 pgs.
“International Application Serial No. PCT/US2005/037977, International Search Report dated Mar. 21, 2006”, 4 pgs.
“International Application Serial No. PCT/US2005/037977, Written Opinion dated Mar. 21, 2006”, 8 pgs.
“International Application Serial No. PCT/US2005/037978, International Preliminary Report on Patentability dated Apr. 24, 2007”, 13 pgs.
“International Application Serial No. PCT/US2005/037979, International Preliminary Report on Patentability dated Apr. 24, 2007”, 9 pgs.
“International Application Serial No. PCT/US2006/033414, International Preliminary Report on Patentability dated Jun. 19, 2008”, 11 pgs.
“International Application Serial No. PCT/US2006/033414, International Search Report dated Mar. 1, 2007”, 5 pgs.
“International Application Serial No. PCT/US2006/033414, Written Opinion dated Mar. 1, 2007”, 9 pgs.
“International Application Serial No. PCT/2006/040291, International Preliminary Report on Patentability dated Jun. 19, 2008”, 11 pgs.
“International Application Serial No. PCT/US2007/065376, International Preliminary Report on Patentability dated Oct. 9, 2008”, 10 pgs.
“International Application Serial No. PCT/US2007/065376, International Search Report dated Dec. 14, 2007”, 5 pgs.
“International Application Serial No. PCT/US2007/065376, Written Opinion dated Dec. 14, 2007”, 11 pgs.
“International Application Serial No. PCT/US2007/074125, International Preliminary Report on Patentability dated Feb. 5, 2009”, 9 pgs.
“International Application Serial No. PCT/US2007/074125, International Search Report dated Dec. 6, 2007”, 4pgs.
“International Application Serial No. PCT/US2007/074125, Written Opinion dated Dec. 6, 2007”, 8 pgs.
“International Application Serial No. PCT/US2007/074135, International Preliminary Report on Patentability dated Feb. 5, 2009”, 9 pgs.
“International Application Serial No. PCT/US2007/078405, International Preliminary Report on Patentability dated Mar. 26, 2009”, 9 pgs.
“International Application Serial No. PCT/US2009/000693, International Preliminary Report on Patentability dated Aug. 19, 2010”, 9 pgs.
“Japanese Application Serial No. 2007-538087, Office Action dated Apr. 17, 2012”, W/ English Translation, 8 pgs.
“Japanese Application Serial No. 2007-538087, Response filed Mar. 23, 2012 to Office Action dated Oct. 5, 2011”, (W/ English Translation of Claims), 9 pgs.
“Japanese Application Serial No. 2007-538087, Response filed Jul. 13, 2012 to Office Action dated Apr. 17, 2012”, (W/ English Translation of Amended Claims), 13 pgs.
“Japanese Application Serial No. 2007-538088, Response filed Mar. 27, 2012 to Final Office Action dated Dec. 6, 2011”, (W/ English Translation of Claims), 11 pgs.
“Japanese Application Serial No. 2008-544324, Office Action dated May 22, 2012”, (W/ English Translation), 5 pgs.
“Japanese Application Serial No. 2008-544324, Response filed Jan. 27, 2012”, (W/ English Translation of Amended Claims), 10 pgs.
“Japanese Application Serial No. 2008-544332, Response filed Mar. 19, 2012 to Office Action dated Nov. 29, 2011”, (W/ English Translation of Claims), 9 pgs.
“Japanese Application Serial No. 2009-503252, Office Action dated Mar. 21, 2012”, (W/ English Translation), 9 pgs.
“Japanese Application Serial No. 2009-503252, Response filed Jun. 20, 2012 to Office Action dated Mar. 21, 2012”, (W/ English Claims), 9 pgs.
“Japanese Application Serial No. 2009-503252, Response filed Oct. 26, 2012 to Office Action dated Oct. 10, 2012”, 7 pgs.
“U.S. Appl. No. 11/549,352, Restriction Requirement dated Aug. 12, 2013”, 5 pgs.
“U.S. Appl. No. 11/683,577, Notice of Allowance dated Mar. 5, 2013”, 11 pgs.
“U.S. Appl. No. 11/854,844, Non Final Office Action dated Jan. 11, 2013”, 15 pgs.
“U.S. Appl. No. 11/854,844, Notice of Allowance dated Sep. 27, 2013”, 9 pgs.
“U.S. Appl. No. 11/854,844, Response filed May 13, 2013 to Non Final Office Action dated Jan. 11, 2013”, 15 pgs.
“U.S. Appl. No. 12/361,884, Notice of Allowance dated Jan. 17, 2014”, 7 pgs.
“U.S. Appl. No. 12/361,884, Notice of Allowance dated Sep. 25, 2013”, 10 pgs.
“U.S. Appl. No. 13/717,027, Preliminary Amendment filed Jun. 25, 2013”, 6 pgs.
“U.S. Appl. No. 13/929,286, Non Final Office Action dated Dec. 11, 2013”, 15 pgs.
“U.S. Appl. No. 13/929,286, Preliminary Amendment filed”, 7 pgs.
“U.S. Appl. No. 14/044,094, Non Final Office Action dated Jan. 17, 2014”, 19 pgs.
“U.S. Appl. No. 14/044,094, Preliminary Amendment filed Oct. 28, 2013”, 8 pgs.
“U.S. Appl. No. 11/316,120, Response filed Jul. 17, 2009 to Non Final Office Action dated Apr. 17, 2009”, 13 pgs.
“U.S. Appl. No. 11/316,120, Response filed Aug. 27, 2010 to Non Final Office Action dated May 27, 2010”, 13 pgs.
“U.S. Appl. No. 11/316,120, Response filed Dec. 22, 2008 to Final Office Action dated Aug. 20, 2008”, 13 pgs.
“U.S. Appl. No. 11/316,120, Supplemental Notice of Allowance dated Sep. 1, 2011”, 4 pgs.
“U.S. Appl. No. 11/394,601, Decision on Pre-Appeal Brief Request mailed Oct. 6, 2010”, 2 pgs.
“U.S. Appl. No. 11/394,601, Final Office Action dated Mar. 22, 2010”, 7 pgs.
“U.S. Appl. No. 11/394,601, Non-Final Office Action dated Sep. 2, 2009”, 7 pgs.
“U.S. Appl. No. 11/394,601, Notice of Allowance dated Dec. 28, 2010”, 8 pgs.
“U.S. Appl. No. 11/394,601, Pre-Appeal Brief Request mailed Jul. 21, 2010”, 5 pgs.
“U.S. Appl. No. 11/394,601, Response filed Dec. 2, 2009 to Non Final Office Action dated Sep. 2, 2009”, 11 pgs.
“U.S. Appl. No. 11/394,601, Restriction Requirement dated Apr. 2, 2009”, 10 pgs.
“U.S. Appl. No. 11/490,576, Decision on Pre-Appeal Brief Request mailed Aug. 30, 2011” 2 pgs.
“U.S. Appl. No. 11/490,576, Final Office Action dated Jan. 19, 2011”, 12 pgs.
“U.S. Appl. No. 11/490,576, Non Final Office Action dated Jul. 9, 2008”, 16 pgs.
“U.S. Appl. No. 11/490,576, Non Final Office Action dated Nov. 9, 2011”, 9 pgs.
“U.S. Appl. No. 11/490,576, Non Final Office Action dated Feb. 17, 2009”, 8 pgs.
“U.S. Appl. No. 11/490,576, Non Final Office Action dated Jul. 12, 2010”, 8 pgs.
“U.S. Appl. No. 11/490,576, Non Final Office Action dated Oct. 5, 2009”, 8 pgs.
“U.S. Appl. No. 11/490,576, Pre-Appeal Brief Request filed May 12, 2011”, 5 pgs.
“U.S. Appl. No. 11/490,576, Response filed Mar. 5, 2010 to Non Final Office Action dated Oct. 5, 2009”, 13 pgs.
“U.S. Appl. No. 11/490,576, Response filed Jun. 17, 2009 to Non Final Office Action dated Feb. 17, 2009”, 13 pgs.
“U.S. Appl. No. 11/490,576, Response filed Oct. 4, 2010 to Non Final Office Action dated Jul. 12, 2010”, 15 pgs.
“U.S. Appl. No. 11/490,576, Response filed Nov. 10, 2010 to Non Final Office Action dated Jul. 9, 2008”, 20 pgs.
“U.S. Appl. No. 11/490,916, Examiner Interview Summary dated Apr. 12, 2010”, 3 pgs.
“U.S. Appl. No. 11/490,916, Examiner Interview Summary dated Aug. 19, 2009”, 2 pgs.
“U.S. Appl. No. 11/490,916, Final Office Action dated Dec. 17, 2009”, 11 pgs.
“U.S. Appl. No. 11/490,916, Non Final Office Action dated May 5, 2009”, 10 pgs.
“U.S. Appl. No. 11/490,916, Notice of Allowance dated Jul. 9, 2010”, 4 pgs.
“U.S. Appl. No. 11/490,916, Response filed Jan. 12, 2009 to Restriction Requirement dated Dec. 11, 2008”, 7 pgs.
“U.S. Appl. No. 11/490,916, Response filed Apr. 15, 2010 to Final Office Action dated Dec. 17, 2009”, 12 pgs.
“U.S. Appl. No. 11/490,916, Response filed Sep. 3, 2009 to Non Final Office Action dated May 5, 2009”, 13 pgs.
“U.S. Appl. No. 11/490,916, Restriction Requirement dated Dec. 11, 2008”, 8 pgs.
“U.S. Appl. No. 11/490,916, Supplemental Notice of Allowability dated Oct. 14, 2010”, 2 pgs.
“U.S. Appl. No. 11/511,152, Final Office Action dated Aug. 10, 2009”, 13 pgs.
“U.S. Appl. No. 11/511,152, Non-Final Office Action dated Dec. 23, 2008”, 14 pgs.
“U.S. Appl. No. 11/511,152, Non-Final Office Action dated Dec. 30, 2009”, 13 pgs.
“U.S. Appl. No. 11/511,152, Notice of Allowance dated Jul. 28, 2010”, 6 pgs.
“U.S. Appl. No. 11/511,152, Preliminary Amendment filed Oct. 17, 2006”, 3 pgs.
“U.S. Appl. No. 11/511,152, Response filed Mar. 23, 2009 to Non Final Office Action dated Dec. 23, 2008”, 11 pgs.
“U.S. Appl. No. 11/511,152, Response filed Jun. 30, 2010 to Non Final Office Action dated Dec. 30, 2009”, 12 pgs.
“U.S. Appl. No. 11/511,152, Response filed Nov. 12, 2009 to Final Office Action dated Aug. 10, 2009”, 13 pgs.
“U.S. Appl. No. 11/549,352, Appeal Brief filed Sep. 9, 2009”, 36 pgs.
“U.S. Appl. No. 11/549,352, Examiner Interview Summary dated Jun. 25, 2008”, 2 pgs.
“U.S. Appl. No. 11/549,352, Examiner's Answer dated Nov. 27, 2009 to Appeal Brief filed Sep. 9, 2009”, 12 pgs.
“U.S. Appl. No. 11/549,352, Final Office Action dated Mar. 9, 2009”, 10 pgs.
“U.S. Appl. No. 11/549,352, Final Office Action dated Aug. 26, 2008”, 13 pgs.
“U.S. Appl. No. 11/549,352, Non-Final Office Action dated Feb. 5, 2008”, 11 pgs.
“U.S. Appl. No. 11/549,352, Notice of Panel Decision from Pre-Appeal Brief Review mailed Feb. 2, 2009”, 2 pgs.
“U.S. Appl. No. 11/549,352, Pre-Appeal Brief for Review filed Dec. 20, 2008”, 5 pgs.
“U.S. Appl. No. 11/549,352, Reply Brief filed Jan. 27, 2010”, 8 pgs.
“U.S. Appl. No. 10/971,550, 312 Amendment filed Mar. 20, 2009”, 6 pgs.
“U.S. Appl. No. 10/971,550, Examiner Interview Summary dated Jan. 22, 2008”, 4 pgs.
“U.S. Appl. No. 10/971,550, Non Final Office Action dated Mar. 19, 2007”, 11 pgs.
“U.S. Appl. No. 10/971,550, Non-Final Office Action dated Nov. 5, 2007”, 19 pgs.
“U.S. Appl. No. 10/971,550, Notice of Allowance dated Jul. 14, 2008”, 4 pgs.
“U.S. Appl. No. 10/971,550, Notice of Allowance dated Dec. 22, 2008” 4 pgs.
“U.S. Appl. No. 10/971,550, PTO Response to 312 Amendment dated Apr. 6, 2009”, 2 pgs.
“U.S. Appl. No. 10/971,550, Response filed Feb. 22, 2007 to Restriction Requirement dated Jan. 22, 2007”, 1 pg.
“U.S. Appl. No. 10/971,500, Response filed Mar. 25, 2008 to Non Final Office Action dated Nov. 5, 2007”, 17 pgs.
“U.S. Appl. No. 10/971,550, Response filed Sep. 4, 2007 to Non-Final Office Action dated Mar. 19, 2007”, 15 pgs.
“U.S. Appl. No. 10/971,550, Restriction Requirement dated Jan. 22, 2007”, 22 pgs.
“U.S. Appl. No. 11/075,375, Restriction Requirement dated Apr. 10, 2007”, 6 pgs.
“U.S. Appl. No. 11/075,375, Examiner Interview Summary dated Jan. 12, 2009”, 4 pgs.
“U.S. Appl. No. 11/075,375, Examiner Interview Summary dated May 1, 2008”, 4 pgs.
“U.S. Appl. No. 11/075,375, Final Office Action dated Jan. 23, 2009”, 10 pgs.
“U.S. Appl. No. 11/075,375, Final Office Action dated Apr. 16, 2009”, 10 pgs.
“U.S. Appl. No. 11/075,375, Non-Final Office Action dated Jun. 8, 2007”, 11 pgs.
“U.S. Appl. No. 11/075,375, Non-Final Office Action dated Aug. 11, 2008”, 15 pgs.
“U.S. Appl. No. 11/075,375, Notice of Allowance dated Sep. 4, 2009”, 6 pgs.
“U.S. Appl. No. 11/075,375, Response filed Jan. 12, 2009 to Non-Final Office Action dated Aug. 11, 2008”, 18 pgs.
“U.S. Appl. No. 11/075,375, Response filed May 7, 2007 to Restriction Requirement dated Apr. 10, 2007”, 8 pgs.
“U.S. Appl. No. 11/075,375, Response filed May 22, 2008 to Final Office Action dated Jan. 23, 2008”, 16 pgs.
“U.S. Appl. No. 11/075,375, Response filed Jul. 16, 2009 to Final Office Action dated Apr. 16, 2009”, 13 pgs.
“U.S. Appl. No. 11/075,375, Response filed Oct. 26, 2007 to Non-Final Office Action dated Jun, 8, 2007”, 10 pgs.
“U.S. Appl. No. 11/075,376, Final Office Action dated Jan. 7, 2008”, 11 pgs.
“U.S. Appl. No. 11/075,376, Non-Final Office Action dated Jun. 26, 2007”, 9 pgs.
“U.S. Appl. No. 11/075,376, Non-Final Office Action dated Aug. 20, 2008”, 16 pgs.
“U.S. Appl. No. 11/075,376, Restriction Requirement dated Apr. 10, 2007”, 6 pgs.
“U.S. Appl. No. 11/075,376, Examiner Interview Summary dated Jan. 12, 2009”, 4 pgs.
“U.S. Appl. No. 11/075,376, Examiner Interview Summary dated Apr. 2, 2008”, 4 pgs.
“U.S. Appl. No. 11/075,376, Final Office Action dated Apr. 8, 2009”, 17 pgs.
“U.S. Appl. No. 11/075,376, Notice of Allowance dated Aug. 24, 2009”, 6 pgs.
“U.S. Appl. No. 11/075,376, Response filed Jan. 21, 2009 to Non-Final Office Action dated Aug. 20, 2008”, 22 pgs.
“U.S. Appl. No. 11/075,376, Response filed May 7, 2007 to Restriction Requirement dated Apr. 10, 2007”, 10 pgs.
“U.S. Appl. No. 11/075,376, Response filed May 7, 2007 to Restriction Requirement dated Apr. 10, 2007”, 8 pgs.
“U.S. Appl. No. 11/075,376, Response filed Jun. 9, 2008 to Final Office Action dated Jan. 7, 2008”, 20 pgs.
“U.S. Appl. No. 11/075,376, Response filed Jul. 8, 2009 to Final Office Action dated Apr. 8, 2009”, 11 pgs.
“U.S. Appl. No. 11/075,376, Response filed Oct. 26, 2007 to Non-Final Office Action dated Jun. 26, 2007”, 14 pgs.
“U.S. Appl. No. 11/316,120, Final Office Action dated Aug. 20, 2008”, 9 pgs.
“U.S. Appl. No. 11/316,120, Non-Final Office Action dated Apr. 17, 2009”, 8 pgs.
“U.S. Appl. No. 11/316,120, Decision on Pre-Appeal Brief Request mailed Apr. 19, 2011”, 2 pgs.
“U.S. Appl. No. 11/316,120, Final Office Action dated Oct. 28, 2010”, 8 pgs.
“U.S. Appl. No. 11/316,120, Final Office Action dated Nov. 12, 2009”, 8 pgs.
“U.S. Appl. No. 11/316,120, Non Final Office Action dated Apr. 11, 2008”, 7 pgs.
“U.S. Appl. No. 11/316,120, Non-Final Office Action dated May 27, 2010”, 7 pgs.
“U.S. Appl. No. 11/316,120, Notice of Allowance dated Jul. 20, 2011”, 7 pgs.
“U.S. Appl. No. 11/316,120, Pre-Appeal Brief Request filed Mar. 25, 2011”, 5 pgs.
“U.S. Appl. No. 11/316,120, Response filed Mar. 25, 2011 to Final Office Action dated Oct. 28, 2010”, 8 pgs.
“U.S. Appl. No. 11/316,120, Response filed Apr. 12, 2010 to Final Office Action dated Nov. 12, 2009”, 12 pgs.
“U.S. Appl. No. 11/316,120, Response filed May 14, 2008 to Non Final Office Action dated Apr. 11, 2008”, 12 pgs.
“U.S. Appl. No. 11/549,352, Response Filed Jul. 7, 2008 to Non-Final Office Action dated Feb. 5, 2008”, 17 pgs.
“U.S. Appl. No. 11/683,577, Examiner Interview Summary dated Jul. 7, 2008”, 4 pgs.
“U.S. Appl. No. 11/683,577, Final Office Action dated Nov. 9, 2009”, 14 pgs.
“U.S. Appl. No. 11/683,577, Non Final Office Action dated Mar. 5, 2009”, 13 pgs.
“U.S. Appl. No. 11/683,577, Response filed May 7, 2010 to Final Office Action dated Nov. 9, 2009”, 14 pgs.
“U.S. Appl. No. 11/683,577, Response filed Aug. 5, 2009 to Non Final Office Action dated Mar. 5, 2009”, 10 pgs.
“U.S. Appl. No. 11/683,584, Non-Final Office Action dated Apr. 1, 2009”, 9 pgs.
“U.S. Appl. No. 11/683,584, Examiner Interview Summary dated Jul. 7, 2009”, 4 pgs.
“U.S. Appl. No. 11/683,584, Final Office Action dated Jan. 29, 2010”, 9 pgs.
“U.S. Appl. No. 11/683,584, Preliminary Amendment filed Mar. 8, 2007”, 1 pgs.
“U.S. Appl. No. 11/683,584, Response filed Jul. 1, 2009 to Non Final Office Action dated Apr. 1, 2009”, 7 pgs.
“U.S. Appl. No. 11/683,584, Response filed Jul. 21, 2010 to Final Office Action dated Jan. 29, 2010”, 12 pgs.
“U.S. Appl. No. 11/745,070, Final Office Action dated Dec. 11, 2009”, 18 pgs.
“U.S. Appl. No. 11/745,070, Non Final Office Action dated Apr. 27, 2009”, 11 pgs.
“U.S. Appl. No. 11/745,070, Response filed Jul. 27, 2009 to Non Final Office Action dated Apr. 27, 2009”, 11 pgs.
“U.S. Appl. No. 11/745,105, Final Office Action dated Mar. 30, 2010”, 9 pgs.
“U.S. Appl. No. 11/745,105, Non Final Office Action dated May 11, 2011”, 13 pgs.
“U.S. Appl. No. 11/745,105, Non Final Office Action dated Sep. 18, 2009”, 9 pgs.
“U.S. Appl. No. 11/745,105, Notice of Allowance dated Oct. 31, 2011”, 5 pgs.
“U.S. Appl. No. 11/745,105, Response filed Jan. 19, 2010 to Non Final Office Action dated Sep. 18, 2009”, 12 pgs.
“U.S. Appl. No. 11/745,105, Response filed Jun. 22, 2009 to Restriction Requirement dated May 21, 2009”, 6 pgs.
“U.S. Appl. No. 11/745,105, Response filed Jul. 29, 2010 to Final Office Action dated Mar. 30, 2010”, 12 pgs.
“U.S. Appl. No. 11/745,105, Response filed Sep. 12, 2011 to Non Final Office Action dated May 11, 2011”, 13 pgs.
“U.S. Appl. No. 11/745,105, Restriction Requirement dated May 21, 2009”, 6 pgs.
“U.S. Appl. No. 12/361,884, Non Final Office Action dated Oct. 12, 2011”, 16 pgs.
“U.S. Appl. No. 12/361,884, Preliminary Amendment filed Jun. 30, 2011”, 12 pgs.
“U.S. Appl. No. 12/361,884,Supplemental Preliminary Amendment filed Jul. 27, 2011”, 12 pgs.
“U.S. Appl. No. 12/365,428, Non Final Office Action dated Aug. 31, 2011”, 9 pgs.
“U.S. Appl. No. 12/910,106, Non Final Office Action dated Apr. 4, 2011”, 9 pgs.
“U.S. Appl. No. 12/910,106, Notice of Allowance dated Jan. 26, 2012”, 6 pgs.
“U.S. Appl. No. 12/910,106,Notice of Allowance dated Oct. 27, 2011”, 5 pgs.
“U.S. Appl. No. 12/910,106, Response filed Aug. 2, 2011 to Non-Final Office Action dated Apr. 4, 2011”, 14 pgs.
“European Application Serial No. 05815206.7, Response filed Apr. 19, 2010 to Communication dated Dec. 18, 2009”, 27 pgs.
“European Application Serial No. 05815206.7, Communication dated Dec. 18, 2009”, 27 pgs.
“European Application Serial No. 05815215.8, Communication dated Dec. 18, 2009”, 2 pgs.
“European Application Serial No. 05815215.8, Response filed Mar. 19, 2010 to Communication dated Dec. 18, 2009”, 12 pgs.
“European Application Serial No. 05817448.3, Communication dated Dec. 18, 2009” 2 pgs.
“European Application Serial No. 05817448.3, Response filed Mar. 19, 2010 to Communication dated Dec. 18, 2009” 2 pgs.
“European Application Serial No. 06790023.3, Office Action dated Mar. 4, 2009”, 7 pgs.
“European Application Serial No. 06825988.6, Office Action dated Mar. 4, 2009”, 7 pgs.
“European Application Serial No. 06847612.6, Office Action dated May 26, 2009”, 3 pgs.
“European Application Serial No. 07759589.0, Office Action dated Jan. 29, 2009”, 3 pgs.
“European Application Serial No. 07759589.0 Office Action dated Feb. 18, 2010”, 3 pgs.
“European Application Serial No. 07759589.0, Response filed Jun. 5, 2009 to Office Action dated Jan. 29, 2009”, 6 pgs.
“European Application Serial No. 07759589.0, Response filed Jun. 24, 2010 to Office Action dated Feb. 18, 2010, 6 pgs., 2009”, 6 pgs.
“European Application Serial No. 07759589.0, Summons to Attend Oral Proceedings dated May 17, 2011”, 3 pgs.
“European Application Serial No. 07759589.0, Written Submission filed Dec. 5, 2011 to Summons to Attend Oral Proceedings dated May 17, 2011”, 16 pgs.
“International Application Serial No. PCT/US2005/037978, International Search Report dated Jun. 13, 2006”, 5 pgs.
“International Application Serial No. PCT/US2005/037978, Written Opinion dated Jun. 13, 2006”, 5 pgs.

Related Publications (1)

	Number	Date	Country
	20190366081 A1	Dec 2019	US

Divisions (1)

	Number	Date	Country
Parent	11490916	Jul 2006	US
Child	12910106		US

Continuations (4)

	Number	Date	Country
Parent	15495612	Apr 2017	US
Child	16541842		US
Parent	15058941	Mar 2016	US
Child	15495612		US
Parent	13476599	May 2012	US
Child	15058941		US
Parent	12910106	Oct 2010	US
Child	13476599		US

Delivery of cardiac stimulation devices

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Term Extension

Abstract